Skip to content
MarketHOT
中文
← Latest news

METROPOLITAN LIFE INSURANCE CO (0000937834) (Filer)

SEC · EDGAR 财务披露 · November 10, 2026 at 4:47 PM ET

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 ______________________________________

Form 10-Q

(Mark One)

☑

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2026

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission file number: 000-55029

 ________________________________________

Metropolitan Life Insurance Company

(Exact name of registrant as specified in its charter)

New York13-5581829
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
200 Park Avenue,

New York,

NY

10166-0188
(Address of principal executive offices)(Zip Code)

(212) 578-9500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

None

N/A

N/A

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☑    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☑   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☑

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐    No ☑

At November 10, 2026, 494,466,664 shares of the registrant’s common stock were outstanding, all of which were owned directly by MetLife, Inc.

REDUCED DISCLOSURE FORMAT

The registrant meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q and is, therefore, filing this Form 10-Q with the reduced disclosure format.


Table of Contents

Page

Part I — Financial Information

Item 1.

Financial Statements (Unaudited) (at September 30, 2026 and December 31, 2025 and for the Three Months and Nine Months Ended September 30, 2026 and 2025)

Interim Condensed Consolidated Balance Sheets

4

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

5

Interim Condensed Consolidated Statements of Equity

6

Interim Condensed Consolidated Statements of Cash Flows

7

Notes to the Interim Condensed Consolidated Financial Statements:

Note 1 — Business, Basis of Presentation and Summary of Significant Accounting Policies

8

Note 2 — Segment Information

10

Note 3 — Future Policy Benefits

10

Note 4 — Policyholder Account Balances

15

Note 5 — Market Risk Benefits

21

Note 6 — Separate Accounts

24

Note 7 — Deferred Policy Acquisition Costs and Value of Business Acquired

27

Note 8 — Investments

28

Note 9 — Derivatives

44

Note 10 — Fair Value

55

Note 11 — Equity

70

Note 12 — Other Revenues and Other Expenses

73

Note 13 — Income Tax

74

Note 14 — Contingencies, Commitments and Guarantees

74

Note 15 — Related Party Transactions

77

Note 16 — Subsequent Events

79

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

80

Item 4.

Controls and Procedures

86

Part II — Other Information

Item 1.

Legal Proceedings

86

Item 1A.

Risk Factors

86

Item 5.

Other Information

86

Item 6. 

Exhibits

87

Glossary

88

Signatures

90


Table of Contents

As used in this Form 10-Q, “MLIC,” the “Company,” “we,” “our” and “us” refer to Metropolitan Life Insurance Company, a New York corporation incorporated in 1868, and its subsidiaries. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”).

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10‑Q, including Management’s Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as “anticipate,” “are confident,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “if,” “intend,” “likely,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would” and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. By their nature, forward-looking statements: speak only as of the date they are made; are not statements of historical fact or guarantees of future performance; and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

Many factors determine Company results, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. We do not guarantee any future performance. Our results could differ materially from those we express or imply in forward-looking statements. The risks, uncertainties and other factors identified in Metropolitan Life Insurance Company’s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:

(1) economic condition difficulties, including risks relating to interest rates, the effects of announced or future tariff increases on the global economy, credit spreads, declining equity or debt markets, real estate, obligors and counterparties, government default or shutdown, derivatives, climate change and public health;

(2) global capital and credit market adversity;

(3) credit facility inaccessibility;

(4) financial strength or credit ratings downgrades;

(5) unavailability, unaffordability, or inadequate reinsurance, including reinsurance risks that arise from reinsurers’ credit risk, and the potential shortfall or failure of risk mitigants to protect against such risks;

(6) statutory life insurance reserve financing costs or limited market capacity;

(7) legal, regulatory, and supervisory and enforcement policy changes;

(8) changes in tax rates, tax laws or interpretations;

(9) litigation and regulatory investigations;

(10) unsuccessful efforts to meet all sustainability standards or to enhance our sustainability;

(11) investment defaults, downgrades, or volatility;

(12) investment sales or lending difficulties;

(13) collateral or derivative-related payments;

(14) investment valuations, allowances, or impairments changes;

(15) claims or other results that differ from our estimates, assumptions, or models;

(16) business competition;

(17) technological changes;

(18) catastrophes;

2


Table of Contents

(19) climate changes or responses to it;

(20) deficiencies in our closed block;

(21) impairment of value of business acquired, value of distribution agreements acquired or value of customer relationships acquired;

(22) product guarantee volatility, costs, and counterparty risks;

(23) risk management failures;

(24) insufficient protection from operational risks;

(25) failure to protect confidentiality, integrity or availability of systems or data or other cybersecurity or disaster recovery failures;

(26) accounting standards changes;

(27) excessive risk-taking; and

(28) marketing and distribution difficulties.

Metropolitan Life Insurance Company does not undertake any obligation to publicly correct or update any forward-looking statement if Metropolitan Life Insurance Company later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures Metropolitan Life Insurance Company makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.

3


Table of Contents

Part I — Financial Information

Item 1. Financial Statements

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Interim Condensed Consolidated Balance Sheets

September 30, 2026 and December 31, 2025 (Unaudited)

(In millions, except share and per share data)

September 30, 2026December 31, 2025
Assets
Investments:

Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $130 and $194, respectively; and amortized cost: $172,684 and $167,384, respectively)

$155,592 $159,332 

Mortgage loans (net of allowance for credit loss of $884 and $701, respectively; includes $132 and $180, respectively, relating to variable interest entities and $65 and $0, respectively, of mortgage loans held-for-sale)

55,140 55,870 
Policy loans5,308 5,596 

Real estate and real estate joint ventures (includes $386 and $378, respectively, under the fair value option; $168 and $64, respectively, of real estate held-for-sale; $2,466 and $2,435, respectively, relating to variable interest entities)

8,492 8,798 
Other limited partnership interests6,449 6,929 
Short-term investments, at estimated fair value2,551 2,221 

Other invested assets (includes $293 and $435, respectively, of leveraged and direct financing leases; $1,928 and $866, respectively, under the fair value option, of which $821 and $0, respectively, relate to variable interest entities; $38 and $45, respectively, relating to variable interest entities not under the fair value option)

16,528 15,086 
Total investments250,060 253,832 

Cash and cash equivalents, principally at estimated fair value (includes $119 and $0, respectively, relating to variable interest entities)

7,993 8,392 
Accrued investment income2,170 2,031 
Premiums, reinsurance and other receivables35,515 35,488 
Market risk benefits, at estimated fair value314 257 
Deferred policy acquisition costs and value of business acquired2,843 2,865 
Current income tax recoverable528 482 
Deferred income tax asset3,081 2,490 
Other assets4,030 4,168 
Separate account assets69,382 73,511 
Total assets$375,916 $383,516 
Liabilities and Equity
Liabilities
Future policy benefits$128,482 $136,432 
Policyholder account balances107,406 104,091 
Market risk benefits, at estimated fair value1,721 2,201 
Other policy-related balances9,057 8,642 
Policyholder dividends payable202 197 
Payables for collateral under securities loaned and other transactions13,045 11,698 
Long-term debt998 1,045 

Notes issued by collateralized financing entities (includes all amounts: under the fair value option; and relating to variable interest entities)

803 — 

Other liabilities (includes $75 and $0, respectively, relating to variable interest entities)

31,657 31,164 
Separate account liabilities69,382 73,511 
Total liabilities362,753 368,981 
Contingencies, Commitments and Guarantees (Note 14)
Equity
Metropolitan Life Insurance Company stockholder’s equity:

Common stock, par value $0.01 per share; 1,000,000,000 shares authorized; 494,466,664 shares issued and outstanding

5 5 
Additional paid-in capital12,475 12,475 
Retained earnings7,905 6,677 
Accumulated other comprehensive income (loss)(7,941)(5,236)
Total Metropolitan Life Insurance Company stockholder’s equity12,444 13,921 
Noncontrolling interests719 614 
Total equity13,163 14,535 
Total liabilities and equity$375,916 $383,516 

See accompanying notes to the interim condensed consolidated financial statements.

4


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

Three Months and Nine Months Ended September 30, 2026 and 2025 (Unaudited)

(In millions)

Three Months
Ended
September 30,
Nine Months
Ended
September 30,
2026202520262025
Revenues
Premiums$6,680 $6,231 $19,844 $19,564 
Universal life and investment-type product policy fees380 369 1,177 1,151 
Net investment income3,314 2,931 9,428 8,613 
Other revenues429 427 1,311 1,283 
Net investment gains (losses)(316)(216)(948)(823)
Net derivative gains (losses)606 (403)699 (1,033)
Total revenues11,093 9,339 31,511 28,755 
Expenses
Policyholder benefits and claims6,827 6,504 20,457 20,510 
Policyholder liability remeasurement (gains) losses74 2 100 8 

Market risk benefit remeasurement (gains) losses

(295)(175)(369)(127)
Interest credited to policyholder account balances992 954 2,876 2,826 
Policyholder dividends98 96 285 320 
Other expenses1,542 1,360 4,677 4,013 
Total expenses9,238 8,741 28,026 27,550 
Income (loss) before provision for income tax1,855 598 3,485 1,205 
Provision for income tax expense (benefit)355 81 644 159 
Net income (loss)1,500 517 2,841 1,046 
Less: Net income (loss) attributable to noncontrolling interests— (4)(7)(9)
Net income (loss) attributable to Metropolitan Life Insurance Company$1,500 $521 $2,848 $1,055 

Comprehensive income (loss)

$(605)$1,568 $136 $3,101 
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax— (4)(7)(9)

Comprehensive income (loss) attributable to Metropolitan Life Insurance Company

$(605)$1,572 $143 $3,110 

See accompanying notes to the interim condensed consolidated financial statements.

5


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Interim Condensed Consolidated Statements of Equity

Nine Months Ended September 30, 2026 and 2025 (Unaudited)

(In millions)

Common
Stock
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Metropolitan Life
Insurance Company
Stockholder’s Equity
Noncontrolling
Interests
Total
Equity
Balance at December 31, 2025$5 $12,475 $6,677 $(5,236)$13,921 $614 $14,535 
Dividends to MetLife, Inc.(1,363)(1,363)(1,363)
Change in equity of noncontrolling interests— 113 113 
Net income (loss)1,348 1,348 (7)1,341 
Other comprehensive income (loss), net of income tax(600)(600)(600)
Balance at June 30, 2026$5 $12,475 $6,662 $(5,836)$13,306 $720 $14,026 
Dividends to MetLife, Inc.(257)(257)(257)
Change in equity of noncontrolling interests— (1)(1)
Net income (loss)1,500 1,500 — 1,500 
Other comprehensive income (loss), net of income tax(2,105)(2,105)(2,105)
Balance at September 30, 2026$5 $12,475 $7,905 $(7,941)$12,444 $719 $13,163 
Common
Stock
Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Income (Loss)
Total
Metropolitan Life
Insurance Company
Stockholder’s Equity
Noncontrolling
Interests
Total
Equity
Balance at December 31, 2024$5 $12,475 $7,444 $(5,994)$13,930 $504 $14,434 
Cumulative effects of change in accounting principles for equity method investee at January 1, 2025(1,074)(1,074)(1,074)
Dividends to MetLife, Inc.(1,966)(1,966)(1,966)
Change in equity of noncontrolling interests— (59)(59)
Net income (loss)534 534 (5)529 
Other comprehensive income (loss), net of income tax1,004 1,004 1,004 
Balance at June 30, 2025$5 $12,475 $6,012 $(6,064)$12,428 $440 $12,868 
Dividends to MetLife, Inc.(219)(219)(219)
Change in equity of noncontrolling interests— (2)(2)
Net income (loss)521 521 (4)517 
Other comprehensive income (loss), net of income tax1,051 1,051 1,051 
Balance at September 30, 2025$5 $12,475 $6,314 $(5,013)$13,781 $434 $14,215 

See accompanying notes to the interim condensed consolidated financial statements.

6


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Interim Condensed Consolidated Statements of Cash Flows

Nine Months Ended September 30, 2026 and 2025 (Unaudited)

(In millions)

Nine Months
Ended
September 30,
20262025
Net cash provided by (used in) operating activities$2,917 $3,356 
Cash flows from investing activities
Sales, maturities and repayments of:
Fixed maturity securities available-for-sale33,905 22,294 
Equity securities92 46 
Fair value option securities220 — 
Mortgage loans8,408 7,051 
Real estate and real estate joint ventures702 136 
Other limited partnership interests506 463 
Short-term investments5,299 5,093 
Purchases and originations of:
Fixed maturity securities available-for-sale(39,021)(25,393)
Equity securities(104)(40)
Fair value option securities(211)— 
Mortgage loans(7,851)(3,860)
Real estate and real estate joint ventures(636)(372)
Other limited partnership interests(457)(298)
Short-term investments(5,547)(4,813)
Cash received in connection with freestanding derivatives1,009 835 
Cash paid in connection with freestanding derivatives(1,753)(1,142)
Net change in policy loans288 (14)
Net change in other invested assets53 462 
Other, net162 75 
Net cash provided by (used in) investing activities(4,936)523 
Cash flows from financing activities
Policyholder account balances - deposits64,460 60,807 
Policyholder account balances - withdrawals(62,575)(63,181)
Net change in payables for collateral under securities loaned and other transactions1,347 343 
Long-term debt repaid(51)(260)

Derivatives with certain financing elements and other derivative-related transactions, net

8 31 
Proceeds from notes issued by collateralized financing entities434 — 
Repayments of notes issued by collateralized financing entities(369)— 
Dividends paid to MetLife, Inc.(1,620)(2,185)
Other, net(12)(71)
Net cash provided by (used in) financing activities1,622 (4,516)
Effect of change in foreign currency exchange rates on cash and cash equivalents balances(2)6 
Change in cash and cash equivalents(399)(631)
Cash and cash equivalents, beginning of period8,392 7,271 
Cash and cash equivalents, end of period$7,993 $6,640 
Supplemental disclosures of cash flow information
Net cash paid (received) for:
Interest$62 $66 
Income tax$505 $557 
Non-cash transactions:
Real estate and real estate joint ventures acquired in satisfaction of debt$77 $128 

Other invested assets received in connection with the sale of other limited partnership interests

$269 $17 

See accompanying notes to the interim condensed consolidated financial statements.

7


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies

Business

Metropolitan Life Insurance Company and its subsidiaries (collectively, “MLIC” or the “Company”) is a provider of insurance, annuities and employee benefits. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”). In the fourth quarter of 2025, the Company reorganized from three reportable segments (Group Benefits, Retirement and Income Solutions (“RIS”) and MetLife Holdings) to a single reportable segment to align with MetLife’s strategic initiatives, and the manner in which the chief operating decision maker (“CODM”) evaluates the performance of the business and allocates resources. Accordingly, certain products were reclassified within the product rollforwards. These changes were applied retrospectively for all periods presented and did not have an impact on prior period consolidated net income (loss). See Note 2 for further information.

Basis of Presentation

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.

The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2025 consolidated balance sheet data was derived from audited consolidated financial statements included in Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2025 Annual Report.

Consolidation

The accompanying interim condensed consolidated financial statements include the accounts of Metropolitan Life Insurance Company and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions are eliminated.

The Company uses either the equity method of accounting or the fair value option (“FVO”) for its investments in joint ventures, including real estate joint ventures (“REJVs”) and other limited partnership interests (“OLPI”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period.

Since the Company is a member of a controlled group of affiliated companies, its results may not be indicative of those of a stand-alone entity.

Recent Accounting Pronouncements

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following table provides a description of ASUs recently issued by the FASB and the impact of their future adoption on the Company’s consolidated financial statements.

8


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)

Future Adoption of Accounting Pronouncements

ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures. ASUs issued but not yet adopted as of September 30, 2026 that are currently being assessed and may or may not have a material impact on the Company’s consolidated financial statements or disclosures are summarized in the table below.

StandardDescriptionEffective Date and
Method of Adoption
Impact on Financial Statements

ASU 2025-08, Financial Instruments—Credit Losses (Topic 326): Purchased Loans

The key amendments include expanding the population of acquired financial assets that are accounted for using the gross-up approach by creating a new category of assets called purchased seasoned loans (“PSLs”), which will be accounted for using the gross-up approach. The day-1 expected credit losses on PSLs will be reflected as an adjustment to the amortized cost basis rather than an expense.Effective for annual and interim periods beginning January 1, 2027, to be applied prospectively (with early adoption permitted).The Company does not expect the adoption of the guidance to have a material impact on its consolidated financial statements.

ASU 2025-06, Intangibles—Goodwill and Other— Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software

The key amendments remove all references to prescriptive and sequential software development project stages and require that an entity capitalize software costs when both: (i) management has authorized and committed to funding the software project; and (ii) it is probable that the project will be completed and the software will be used to perform the function intended.

Effective for annual and interim periods beginning January 1, 2028, to be applied either prospectively, retrospectively, or using a modified transition approach (with early adoption permitted as of the beginning of an annual reporting period).The Company is evaluating the impact of the guidance on its consolidated financial statements.

ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as amended by ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying The Effective Date

The key amendments require disclosures in the notes to financial statements around employee compensation costs, depreciation, intangible asset amortization and certain other costs and expenses. Information on selling expenses is also required.

Effective for annual periods beginning January 1, 2027, and
interim periods beginning January 1, 2028, to be applied prospectively with an option for retrospective application (with early adoption permitted).
The Company is evaluating the impact of the guidance on its consolidated financial statements.

9


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

2. Segment Information

In the fourth quarter of 2025, the Company reorganized from three reportable segments (Group Benefits, RIS and MetLife Holdings) to a single reportable segment and changed the measure used to evaluate segment profitability from adjusted earnings to net income. See Note 1. The CODM is the Company’s chief executive officer, who evaluates performance and decides how to allocate resources based on net income as reported on the interim condensed consolidated statements of operations. The significant segment expenses provided to the CODM are consistent with the categories shown in the Company’s interim condensed consolidated statements of operations, and there are no other segment expenses at a more disaggregated level used by the CODM. The measure of segment assets is reported on the interim condensed consolidated balance sheets as total assets.

3. Future Policy Benefits

The Company establishes liabilities for amounts payable under insurance policies. These liabilities are comprised of traditional and limited-payment contracts and associated deferred profit liability (“DPL”), additional insurance liabilities, participating life and short-duration contracts.

The Company’s future policy benefits (“FPBs”) on the interim condensed consolidated balance sheets were as follows at:

September 30, 2026December 31, 2025
(In millions)

Traditional and Limited-Payment Contracts:

Annuities

$51,443 $57,127 

Long-term care

13,764 15,224 
Deferred Profit Liabilities:

Annuities

3,005 3,075 
Additional Insurance Liabilities:

Universal and variable universal life

2,238 2,127 

Participating life

40,769 41,624 
Other long-duration (1)6,125 6,313 
Short-duration and other 11,138 10,942 
Total$128,482 $136,432 

__________________

(1)This balance represents liabilities for various smaller product lines.

Rollforwards — Traditional and Limited-Payment Contracts

The following information about the direct and assumed liability for FPBs includes disaggregated rollforwards of expected future net premiums and expected future benefits. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in the rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers, except with respect to ending net liability for FPB balances where applicable.

10


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Future Policy Benefits (continued)

Annuities

The Company’s annuity products include pension risk transfers, certain structured settlements and certain institutional income annuities, which are mainly single premium spread-based products. The Company reinsures portions of certain pension risk transfers on a modified coinsurance basis. Information regarding these products was as follows:

Nine Months
Ended
September 30,
20262025
(Dollars in millions)
Present Value of Expected Net Premiums

Balance, beginning of period, at current discount rate at balance sheet date

$— $— 

Balance, beginning of period, at original discount rate

$— $— 

Effect of changes in cash flow assumptions (1)

— — 

Effect of actual variances from expected experience (2)

17 (21)

Adjusted balance

17 (21)
Issuances661 1,278 

Net premiums collected

(678)(1,257)

Ending balance at original discount rate

— — 

Balance, end of period, at current discount rate at balance sheet date

$— $— 

Present Value of Expected FPBs

Balance, beginning of period, at current discount rate at balance sheet date

$57,446 $47,910 
Balance, beginning of period, at original discount rate$57,896 $49,191 
Effect of changes in cash flow assumptions (1)68 (67)
Effect of actual variances from expected experience (2)(12)(58)

Adjusted balance

57,952 49,066 
     Issuances666 1,286 
     Interest accrual2,127 1,840 
     Benefit payments(4,151)(3,514)

Ending balance at original discount rate

56,594 48,678 
Effect of changes in discount rate assumptions(4,608)(69)

Balance, end of period, at current discount rate at balance sheet date

51,986 48,609 

Cumulative amount of fair value hedging adjustments

(543)(277)

Net liability for FPBs

51,443 48,332 

Less: Reinsurance recoverables

3,883 — 

Net liability for FPBs, net of reinsurance

$47,560 $48,332 

Undiscounted - Expected future benefit payments

$103,962 $92,094 
Discounted - Expected future benefit payments (at current discount rate at balance sheet date)$51,986 $48,609 
Weighted-average duration of the liability8 years9 years
Weighted-average interest accretion (original locked-in) rate5.1 %5.1 %
Weighted-average current discount rate at balance sheet date6.5 %5.3 %

__________________

(1)For the nine months ended September 30, 2025, the net effect of changes in cash flow assumptions was substantially offset by the corresponding impact in DPL associated with the Company’s annuity products of $63 million.

(2)For the nine months ended September 30, 2025, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the Company’s annuity products of $31 million.

11


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Future Policy Benefits (continued)

Long-term Care

The Company’s long-term care products offer protection against potentially high costs of long-term health care services. Information regarding these products was as follows:

Nine Months
Ended
September 30,
20262025
(Dollars in millions)
Present Value of Expected Net Premiums

Balance, beginning of period, at current discount rate at balance sheet date

$5,548 $5,475 

Balance, beginning of period, at original discount rate

$5,515 $5,568 

Effect of changes in cash flow assumptions

108 68 

Effect of actual variances from expected experience

107 99 

Adjusted balance

5,730 5,735 
Interest accrual212 212 

Net premiums collected

(425)(421)

Ending balance at original discount rate

5,517 5,526 
Effect of changes in discount rate assumptions(353)57 

Balance, end of period, at current discount rate at balance sheet date

$5,164 $5,583 

Present Value of Expected FPBs

Balance, beginning of period, at current discount rate at balance sheet date

$20,772 $20,012 
Balance, beginning of period, at original discount rate$21,490 $21,024 

Effect of changes in cash flow assumptions

115 66 
Effect of actual variances from expected experience165 149 

Adjusted balance

21,770 21,239 
     Interest accrual852 833 
     Benefit payments(753)(690)

Ending balance at original discount rate

21,869 21,382 
Effect of changes in discount rate assumptions(2,941)(490)

Balance, end of period, at current discount rate at balance sheet date

18,928 20,892 

Net liability for FPBs

$13,764 $15,309 

Undiscounted:

Expected future gross premiums$10,249 $10,462 

Expected future benefit payments

$45,218 $44,833 
Discounted (at current discount rate at balance sheet date):
Expected future gross premiums$6,469 $7,059 
Expected future benefit payments$18,928 $20,892 
Weighted-average duration of the liability12 years13 years

Weighted-average interest accretion (original locked-in) rate

5.4 %5.4 %
Weighted-average current discount rate at balance sheet date6.8 %5.6 %

For the nine months ended September 30, 2026, the net effect of changes in cash flow assumptions was primarily driven by updates in policyholder behavior related to lapses and cost of care, as well as morbidity assumptions related to future incidence. This was substantially offset by updates in operational assumptions related to future premium rate increases and morbidity assumptions related to incurred but not reported development. For the nine months ended September 30, 2025, the net effect of changes in cash flow assumptions was primarily driven by updates in operational assumptions related to future premium rate increases, substantially offset by unfavorable morbidity and policyholder behavior related to lapses.

For the nine months ended September 30, 2026 and 2025, the net effect of actual variances from expected experience was primarily driven by unfavorable mortality and morbidity, partially offset by future premium rate increases.

12


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Future Policy Benefits (continued)

Significant Methodologies and Assumptions

The principal inputs used in the establishment of the FPB reserve for long-term care products include actual premiums, actual benefits, in-force data, locked-in claim-related expenses, the locked-in interest accretion rate, the current upper-medium grade discount rate at the balance sheet date and best estimate assumptions. The best estimate assumptions include mortality, lapse, incidence, claim utilization, claim cost inflation, claim continuance, and premium rate increases.

Rollforward — Additional Insurance Liabilities

The Company establishes additional insurance liabilities for annuitization, death or other insurance benefits for universal life and variable universal life contract features whereby the Company guarantees to the contractholder either a secondary guarantee or a guaranteed paid-up benefit. The policy can remain in force, even if the base policy account value is zero, as long as contractual secondary guarantee requirements have been met.

The following information about the direct liability for additional insurance liabilities includes a disaggregated rollforward. The products grouped within the rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies. The adjusted balance in the disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in the rollforward and accompanying financial information do not include a reduction for amounts ceded to reinsurers.

Universal and Variable Universal Life

The Company’s universal and variable universal life products provide a contract feature whereby the Company guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding these additional insurance liabilities was as follows:

Nine Months
Ended
September 30,
20262025
Universal and Variable Universal Life
(Dollars in millions)
Balance, beginning of period$2,127 $1,969 
Less: Accumulated other comprehensive income (loss) (“AOCI”) adjustment(13)(17)
Balance, beginning of period, before AOCI adjustment2,140 1,986 
Effect of changes in cash flow assumptions19 (19)
Effect of actual variances from expected experience38 24 
Adjusted balance2,197 1,991 
Assessments accrual69 68 
Interest accrual83 77 
Excess benefits paid(93)(64)
Balance, end of period, before AOCI adjustment2,256 2,072 
Add: AOCI adjustment (18)(13)
Balance, end of period2,238 2,059 
Less: Reinsurance recoverables2,238 2,059 
Balance, end of period, net of reinsurance$— $— 
Weighted-average duration of the liability15 years16 years
Weighted-average interest accretion rate5.2 %5.2 %

13


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Future Policy Benefits (continued)

The Company’s gross premiums or assessments and interest expense recognized in the interim condensed consolidated statements of operations and comprehensive income (loss) for long-duration contracts, excluding participating life contracts, were as follows:

Nine Months
Ended
September 30,
20262025
Gross Premiums or Assessments (1)Interest Expense (2)Gross Premiums or Assessments (1)Interest Expense (2)
(In millions)
Traditional and Limited-Payment Contracts:

Annuities

$732 $2,127 $1,305 $1,840 

Long-term care

537 640 539 621 
Deferred Profit Liabilities:

Annuities

N/A113 N/A114 
Additional Insurance Liabilities:

Universal and variable universal life

245 83 262 77 

Other long-duration

1,417 228 687 228 
 Total $2,931 $3,191 $2,793 $2,880 

__________________

(1)Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income.

(2)Interest expense is included in policyholder benefits and claims.

Liabilities for Unpaid Claims and Claim Expenses

Rollforward of Claims and Claim Adjustment Expenses

Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows:

Nine Months
Ended
September 30,
20262025
(In millions)
Balance, beginning of period$11,956 $11,698 
Less: Reinsurance recoverables1,946 2,004 
Net balance, beginning of period10,010 9,694 
Incurred related to:
Current period15,797 16,010 
Prior periods (1)(253)(256)
Total incurred15,544 15,754 
Paid related to:
Current period(10,503)(10,533)
Prior periods(4,609)(4,543)
Total paid(15,112)(15,076)
Net balance, end of period10,442 10,372 
Add: Reinsurance recoverables2,102 2,051 
Balance, end of period (included in FPBs and other policy-related balances)$12,544 $12,423 

__________________

14


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

3. Future Policy Benefits (continued)

(1)For the nine months ended September 30, 2026 and 2025, incurred claims and claim adjustment expenses associated with prior periods decreased due to favorable claims experience in the respective current period.

4. Policyholder Account Balances

The Company establishes liabilities for policyholder account balances (“PABs”), which are generally equal to the account value, and which include accrued interest credited, but exclude the impact of any applicable charge that may be incurred upon surrender.

The Company’s PABs on the interim condensed consolidated balance sheets were as follows at:

September 30, 2026December 31, 2025
(In millions)

Life

$10,333 $10,197 
Capital markets investment products and stable value guaranteed interest contracts (“GICs”)62,141 59,278 
Annuities and risk solutions17,051 15,671 
Fixed and variable annuities5,304 5,788 
Other 12,577 13,157 
Total $107,406 $104,091 

Rollforwards

The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance.

15


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Policyholder Account Balances (continued)

Life

The life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account portion of variable life insurance products. Information regarding this liability was as follows:

Nine Months
Ended
September 30,
20262025

(Dollars in millions)

Balance, beginning of period$10,197 $7,469 

Transfer (1)

— 3,084 

Deposits

3,708 2,791 

Policy charges

(499)(504)
Surrenders and withdrawals(3,260)(2,758)

Benefit payments

(8)(7)

Net transfers from (to) separate accounts

3 2 
Interest credited192 196 
Balance, end of period$10,333 $10,273 

Weighted-average annual crediting rate

2.5 %2.5 %
At period end:
Cash surrender value$10,257 $10,205 

Net amount at risk, excluding offsets from reinsurance:

In the event of death

$268,851 $266,256 

__________________

(1)Reported balances for the nine months ended September 30, 2025 have been updated to include a product previously not included in the disaggregated rollforward. See Note 1.

16


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Policyholder Account Balances (continued)

The life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)
September 30, 2026

Equal to or greater than 0% but less than 2%

$520 $— $613 $4,554 $5,687 

Equal to or greater than 2% but less than 4%

3,708 91 76 — 3,875 

Equal to or greater than 4%

653 24 — 64 741 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A30 
Total$4,881 $115 $689 $4,618 $10,333 
September 30, 2025

Equal to or greater than 0% but less than 2%

$489 $— $678 $4,143 $5,310 

Equal to or greater than 2% but less than 4%

4,008 98 60 — 4,166 

Equal to or greater than 4%

683 25 3 52 763 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A34 
Total$5,180 $123 $741 $4,195 $10,273 

Capital Markets Investment Products and Stable Value GICs

The capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows:

Nine Months
Ended
September 30,
20262025

(Dollars in millions)

Balance, beginning of period$59,278 $57,799 

Deposits

58,031 56,275 
Surrenders and withdrawals(56,381)(57,731)
Interest credited1,635 1,613 

Effect of foreign currency translation and other, net

(422)1,560 
Balance, end of period$62,141 $59,516 

Weighted-average annual crediting rate

3.7 %3.7 %

Cash surrender value at period end

$1,477 $927 

17


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Policyholder Account Balances (continued)

The capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)
September 30, 2026

Equal to or greater than 0% but less than 2%

$— $— $— $2,554 $2,554 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A59,587 
Total$— $— $— $2,554 $62,141 
September 30, 2025

Equal to or greater than 0% but less than 2%

$— $— $— $2,728 $2,728 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A56,788 
Total$— $— $— $2,728 $59,516 

Annuities and Risk Solutions

The annuity and risk solutions PABs include certain structured settlements and institutional income annuities, group fixed deferred annuities, the fixed account portion of group variable deferred annuities, registered index-linked annuities and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows:

Nine Months
Ended
September 30,
20262025

(Dollars in millions)

Balance, beginning of period$15,671 $11,673 

Transfer (1)

— 3,109 

Deposits

1,874 1,140 

Policy charges

(141)(138)
Surrenders and withdrawals(784)(490)

Benefit payments

(509)(489)

Net transfers from (to) separate accounts

6 42 
Interest credited501 463 

Other

433 18 
Balance, end of period$17,051 $15,328 

Weighted-average annual crediting rate

4.1 %4.2 %
At period end:
Cash surrender value$12,036 $10,660 

Net amount at risk, excluding offsets from reinsurance:

In the event of death

$34,013 $34,310 

At annuitization or exercise of other living benefits

$16 $13 

__________________

18


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Policyholder Account Balances (continued)

(1)A product previously reported within Fixed and Variable Annuities has been moved to Annuities and Risk Solutions. Accordingly, the reported balances for the nine months ended September 30, 2025 have been updated to reflect this change. See Note 1.

The annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)
September 30, 2026

Equal to or greater than 0% but less than 2%

$— $— $8 $2,898 $2,906 

Equal to or greater than 2% but less than 4%

462 2,033 454 53 3,002 

Equal to or greater than 4%

3,430 — 163 6 3,599 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A7,544 
Total$3,892 $2,033 $625 $2,957 $17,051 
September 30, 2025

Equal to or greater than 0% but less than 2%

$— $— $8 $2,523 $2,531 

Equal to or greater than 2% but less than 4%

377 2,368 487 52 3,284 

Equal to or greater than 4%

3,629 11 292 7 3,939 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A5,574 
Total$4,006 $2,379 $787 $2,582 $15,328 

19


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Policyholder Account Balances (continued)

Fixed and Variable Annuities

The fixed and variable annuity PABs primarily include fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows:

Nine Months
Ended
September 30,
20262025

(Dollars in millions)

Balance, beginning of period$5,788 $9,513 

Transfer (1)

— (3,109)
Deposits68 73 

Policy charges

(6)(7)
Surrenders and withdrawals(558)(641)
Benefit payments(201)(234)
Net transfers from (to) separate accounts84 199 
Interest credited127 141 

Other

2 3 
Balance, end of period$5,304 $5,938 

Weighted-average annual crediting rate

3.1 %3.1 %
At period end:
Cash surrender value$4,806 $5,390 

Net amount at risk, excluding offsets from reinsurance (2):

In the event of death

$2,332 $2,264 

At annuitization or exercise of other living benefits

$708 $640 

__________________

(1)A product previously reported within Fixed and Variable Annuities has been moved to Annuities and Risk Solutions. Accordingly, the reported balances for the nine months ended September 30, 2025 have been updated to reflect this change. See Note 1.

(2)Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as market risk benefits (“MRBs”), which are disclosed in “Annuities” in Note 5.

20


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

4. Policyholder Account Balances (continued)

The fixed and variable annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at:

Range of GMCRAt GMCRGreater than
 0% but less
 than 0.50% above GMCR
Equal to or greater than 0.50% but less than 1.50%
 above GMCR
Equal to or greater than 1.50% above GMCRTotal
Account
Value
(In millions)
September 30, 2026

Equal to or greater than 0% but less than 2%

$32 $16 $457 $160 $665 

Equal to or greater than 2% but less than 4%

2,424 1,387 224 34 4,069 

Equal to or greater than 4%

107 166 — — 273 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A297 
Total$2,563 $1,569 $681 $194 $5,304 
September 30, 2025

Equal to or greater than 0% but less than 2%

$40 $10 $473 $161 $684 

Equal to or greater than 2% but less than 4%

2,540 1,707 303 78 4,628 

Equal to or greater than 4%

167 130 1 — 298 

Products with either a fixed rate or no GMCR

N/AN/AN/AN/A328 
Total$2,747 $1,847 $777 $239 $5,938 

5. Market Risk Benefits

The Company establishes assets and liabilities for variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit, less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets.

The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at:

September 30, 2026December 31, 2025
AssetLiability

Net Liability (Asset)

AssetLiability

Net Liability (Asset)

(In millions)

Annuities

$267 $1,618 $1,351 $216 $2,043 $1,827 

Other

47 103 56 41 158 117 

Total

$314 $1,721 $1,407 $257 $2,201 $1,944 

Rollforwards

The following information about the direct and assumed liabilities (assets) for MRBs includes a disaggregated rollforward. The products grouped within this rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies.

21


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Market Risk Benefits (continued)

Annuities

The Company’s variable annuity products offer contract features whereby the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantee contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. Information regarding the Company’s variable annuity products was as follows:

Nine Months
Ended
September 30,
20262025
(In millions)

Balance, beginning of period (1)

$1,827 $2,069 
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$1,742 $2,026 
Transfer, beginning of period, before effect of cumulative changes in the instrument-specific credit risk (1)— (191)
Attributed fees collected178 195 
Benefit payments(73)(68)
Effect of changes in interest rates(524)(7)
Effect of changes in capital markets(256)(368)
Effect of changes in equity index volatility45 7 
Actual policyholder behavior different from expected behavior150 149 
Effect of changes in future expected policyholder behavior and other assumptions(6)(13)

Effect of foreign currency translation and other, net

57 169 
Effect of changes in risk margin(64)(3)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk1,249 1,896 
Cumulative effect of changes in the instrument-specific credit risk102 70 
Balance, end of period1,351 1,966 
Less: Reinsurance recoverable63 — 
Balance, end of period, net of reinsurance$1,288 $1,966 
At period end:

Net amount at risk, excluding offsets from hedging and reinsurance (2):

In the event of death$2,332 $2,264 
At annuitization or exercise of other living benefits$708 $640 
Weighted-average attained age of contractholders:
In the event of death73 years72 years
At annuitization or exercise of other living benefits72 years71 years

__________________

(1)    A product previously reported within Annuities has been moved to Other. Accordingly, the reported balances for the nine months ended September 30, 2025 have been updated to reflect this change. The transfer amount related to the balance at January 1, 2025 was ($165) million. See Note 1.

(2)    Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs, which are disclosed in “Fixed and Variable Annuities” in Note 4.

Significant Methodologies and Assumptions

The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured, in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in other comprehensive income (loss) (“OCI”).

22


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Market Risk Benefits (continued)

The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates.

Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 10 for additional information on significant unobservable inputs.

The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc.

Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees.

These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions, including changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI.

Other

In addition to the disaggregated MRB product rollforward above, the Company offers other products with guaranteed minimum benefit features. These MRBs are measured at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 10 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding these product liabilities (assets) was as follows:

Nine Months
Ended
September 30,
20262025
(In millions)

Balance, beginning of period (1)

$117 $24 
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk$138 $29 
Transfer, beginning of period, before effect of cumulative changes in the instrument-specific credit risk (1)— 191 
Attributed fees collected11 12 
Effect of changes in interest rates(70)(31)
Effect of changes in capital markets(15)(28)
Effect of changes in equity index volatility12 3 
Actual policyholder behavior different from expected behavior3 (5)
Effect of changes in future expected policyholder behavior and other assumptions(4)(2)
Effect of foreign currency translation and other, net 5 12 
Effect of changes in risk margin(5)1 
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk75 182 
Cumulative effect of changes in the instrument-specific credit risk(19)(26)
Balance, end of period$56 $156 

23


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

5. Market Risk Benefits (continued)

__________________

(1)A product previously reported within Annuities has been moved to Other. Accordingly, the reported balances for the nine months ended September 30, 2025 have been updated to reflect this change. The transfer amount related to the balance at January 1, 2025 was $165 million. See Note 1.

6. Separate Accounts

Separate account assets consist of investment accounts established and maintained by the Company. The investment objectives of these assets are directed by the contractholder. An equivalent amount is reported as separate account liabilities. These accounts are reported separately from the general account assets and liabilities.

Separate Account Liabilities

The Company’s separate account liabilities on the interim condensed consolidated balance sheets were as follows at:

September 30, 2026December 31, 2025
(In millions)

Stable value and risk solutions

$25,678 $27,605 

Group annuities

17,115 18,099 

Variable annuities

18,028 19,554 

Other

8,561 8,253 

Total

$69,382 $73,511 

Rollforwards

The following information about the separate account liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies.

The separate account liabilities are primarily comprised of the following: stable value and risk solutions contracts, participating and non-participating group annuity contracts and variable annuities.

24


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Separate Accounts (continued)

The balances of and changes in separate account liabilities were as follows:

Stable Value and Risk Solutions

Group

Annuities

Variable

Annuities

(In millions)
Nine Months Ended September 30, 2026
Balance, beginning of period$27,605 $18,099 $19,554 
Premiums and deposits925 176 52 
Policy charges(160)(80)(326)
Surrenders and withdrawals(2,205)(1,363)(1,832)
Benefit payments(138)(32)(331)
Investment performance112 228 999 
Net transfers from (to) general account9 (14)(85)
Other (470)101 (3)
Balance, end of period$25,678 $17,115 $18,028 
Nine Months Ended September 30, 2025
Balance, beginning of period$32,761 $11,001 $27,766 

Transfer, January 1 (1)

— 6,926 (6,926)
Premiums and deposits1,277 197 49 
Policy charges(157)(80)(351)
Surrenders and withdrawals(6,037)(1,212)(1,892)
Benefit payments(96)(30)(314)
Investment performance1,843 1,592 2,055 
Net transfers from (to) general account26 (69)(200)
Other (2)(2,331)25 (1)
Balance, end of period$27,286 $18,350 $20,186 

Cash surrender value at September 30, 2026 (3)

$23,576 $6,847 $17,907 

Cash surrender value at September 30, 2025 (3)

$24,944 $7,098 $20,068 

__________________

(1)    A product previously reported within Variable Annuities has been moved to Group Annuities. Accordingly, the reported balances for the nine months ended September 30, 2025 have been updated to reflect this change. See Note 1.

(2)    Other for stable value and risk solutions primarily includes changes related to unsettled trades of mortgage-backed securities.

(3)    Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges.

25


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

6. Separate Accounts (continued)

Separate Account Assets

The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at:

September 30, 2026December 31, 2025
(In millions)

Fixed maturity securities:

Bonds:

Government and agency

$7,700 $8,645 
Public utilities917 1,010 
Municipals227 265 
Corporate bonds6,761 7,426 
Total bonds15,605 17,346 
Mortgage-backed securities7,074 7,640 
Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)1,960 1,976 
Redeemable preferred stock7 8 
Total fixed maturity securities24,646 26,970 
Equity securities2,801 2,775 

Mutual funds:

Bond funds

2,795 3,050 

Equity funds

20,572 20,637 

Balanced funds

194 172 

Other

14,133 15,068 

Total mutual funds

37,694 38,927 
Other invested assets1,042 1,152 
Total investments66,183 69,824 

Other assets

3,199 3,687 
Total$69,382 $73,511 

26


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

7. Deferred Policy Acquisition Costs and Value of Business Acquired

Information regarding total deferred policy acquisition costs (“DAC”) and value of business acquired (“VOBA”) was as follows:

Nine Months
Ended
September 30,
2026

2025 (1)

(In millions)

DAC (2):

Balance, beginning of period

$2,855 $3,124 
Capitalizations169 79 
Amortization(189)(198)

Balance, end of period

$2,835 $3,005 
Total DAC and VOBA:
Balance at September 30, 2026$2,843 
Balance at September 30, 2025$3,015 

Balance at December 31, 2025

$2,865 

__________________

(1)See Note 2 for information on the Company’s reorganization to a single segment.

(2)Includes DAC balances primarily related to whole life, variable annuities, disability income, term life, long-term care and universal life products.

27


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments

Fixed Maturity Securities Available-for-Sale

Fixed Maturity Securities Available-for-Sale by Sector

The following table presents fixed maturity securities available-for-sale (“AFS”) by sector. United States (“U.S.”) corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, prime investor, nonqualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans, broadly syndicated bank loans and other assets. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.”

September 30, 2026December 31, 2025
Amortized
Cost
Gross UnrealizedEstimated
Fair
Value
Amortized
Cost
Gross UnrealizedEstimated
Fair
Value
SectorAllowance for
Credit Loss (“ACL”)
GainsLossesACLGainsLosses
(In millions)
U.S. corporate$54,325 $(74)$251 $5,203 $49,299 $52,552 $(125)$1,050 $2,875 $50,602 
RMBS29,588 (1)124 2,466 27,245 28,129 (1)476 1,365 27,239 
U.S. government and agency25,986 — 21 4,880 21,127 29,811 — 188 3,298 26,701 
Foreign corporate29,067 (3)216 3,174 26,106 27,934 (7)742 2,198 26,471 
ABS & CLO18,638 — 67 476 18,229 14,610 (5)137 191 14,551 
Municipals5,735 — 12 841 4,906 5,947 — 138 496 5,589 
CMBS5,366 (16)8 304 5,054 5,286 (20)57 210 5,113 
Foreign government3,979 (36)58 375 3,626 3,115 (36)151 164 3,066 
Total fixed maturity securities AFS$172,684 $(130)$757 $17,719 $155,592 $167,384 $(194)$2,939 $10,797 $159,332 

Maturities of Fixed Maturity Securities AFS

The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at September 30, 2026:

Due in One
Year or Less
Due After
 One Year
Through
Five Years
Due After
Five Years
Through Ten
Years
Due After
Ten Years
Structured
Products
Total Fixed
Maturity
Securities
AFS
(In millions)
Amortized cost, net of ACL$4,793 $27,351 $28,659 $58,176 $53,575 $172,554 
Estimated fair value$4,751 $26,527 $27,032 $46,754 $50,528 $155,592 

Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity.

28


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector

The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position.

September 30, 2026December 31, 2025
Less than 12 MonthsEqual to or Greater
than 12 Months
Less than 12 MonthsEqual to or Greater
than 12 Months
Sector & Credit QualityEstimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
Estimated
Fair
Value
Gross
Unrealized
Losses
(Dollars in millions)
U.S. corporate$21,491 $1,187 $17,526 $4,003 $4,208 $80 $20,765 $2,763 
RMBS17,077 741 6,931 1,724 1,728 17 9,165 1,348 
U.S. government and agency8,859 366 9,174 4,514 6,209 57 10,238 3,241 
Foreign corporate10,485 564 9,902 2,609 1,211 69 11,682 2,126 
ABS & CLO9,367 288 1,990 188 3,570 22 2,534 169 
Municipals2,592 181 1,783 660 588 14 1,961 482 
CMBS2,412 79 1,628 223 421 9 2,081 199 
Foreign government1,914 129 898 245 167 4 1,078 159 
Total fixed maturity securities AFS$74,197 $3,535 $49,832 $14,166 $18,102 $272 $59,504 $10,487 
Investment grade$70,924 $3,390 $48,868 $14,042 $17,172 $232 $58,276 $10,396 

Below investment grade

3,273 145 964 124 930 40 1,228 91 
Total fixed maturity securities AFS$74,197 $3,535 $49,832 $14,166 $18,102 $272 $59,504 $10,487 
Total number of securities in an

unrealized loss position

8,1625,2442,7785,880

Evaluation of Fixed Maturity Securities AFS for Credit Loss

Evaluation and Measurement Methodologies

See “Fixed Maturity Securities AFS — Evaluation of Fixed Maturity Securities AFS for Credit Loss — Evaluation and Measurement Methodologies” in Note 10 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report.

Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position

Gross unrealized losses on securities without an ACL increased $6.9 billion for the nine months ended September 30, 2026 to $17.7 billion primarily due to an increase in interest rates.

As shown in the table above, most of the gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater at September 30, 2026, relate to investment grade securities. These unrealized losses are principally due to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase.

As of September 30, 2026, $124 million of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater on below investment grade securities were concentrated in the consumer, communications and industrial sectors within corporate securities and in foreign government securities. These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty and, with respect to fixed-rate securities, rising interest rates since purchase.

At September 30, 2026, the Company did not intend to sell its securities in an unrealized loss position without an ACL, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Therefore, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at September 30, 2026.

29


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation.

Rollforward of ACL for Fixed Maturity Securities AFS By Sector

The rollforward of ACL for fixed maturity securities AFS by sector was as follows:

U.S.
 Corporate
Foreign CorporateForeign
Government
RMBSABS & CLOCMBSTotal
Three Months Ended September 30, 2026(In millions)
Balance, beginning of period$93 $12 $36 $1 $— $16 $158 
ACL not previously recorded— — — — — — — 
Changes for securities with previously recorded ACL5 — — — — — 5 
Securities sold or exchanged(24)(9)— — — — (33)
Balance, end of period$74 $3 $36 $1 $— $16 $130 
Three Months Ended September 30, 2025
Balance, beginning of period$49 $— $36 $2 $4 $12 $103 
ACL not previously recorded65 — — — — — 65 
Changes for securities with previously recorded ACL25 — — — 1 2 28 
Securities sold or exchanged— — — — — — — 
Balance, end of period$139 $— $36 $2 $5 $14 $196 
U.S.
 Corporate
Foreign CorporateForeign
Government
RMBSABS & CLOCMBSTotal
Nine Months Ended September 30, 2026(In millions)
Balance, beginning of period$125 $7 $36 $1 $5 $20 $194 
ACL not previously recorded— 16 — — — 3 19 
Changes for securities with previously recorded ACL26 (4)— — — 4 26 
Securities sold or exchanged(77)(16)— — (5)(11)(109)
Balance, end of period$74 $3 $36 $1 $— $16 $130 
Nine Months Ended September 30, 2025
Balance, beginning of period$45 $15 $36 $1 $7 $8 $112 
ACL not previously recorded81 — — 1 — 3 85 
Changes for securities with previously recorded ACL36 (2)— — 1 3 38 
Securities sold or exchanged(23)(13)— — (3)— (39)
Balance, end of period$139 $— $36 $2 $5 $14 $196 

30


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Mortgage Loans

Mortgage Loans by Portfolio Segment

Mortgage loans are summarized as follows at:

September 30, 2026December 31, 2025
Portfolio SegmentCarrying
Value
% of
Total
Carrying
Value
% of
Total

(Dollars in millions)

Commercial $26,473 48.1 %$29,546 52.9 %
Agricultural15,185 27.5 15,203 27.2 
Residential14,301 26.0 11,815 21.2 
Total amortized cost55,959 101.6 56,564 101.3 

ACL

(884)(1.6)(701)(1.3)
Total mortgage loans held-for-investment, net55,075 100.0 55,863 100.0 
Mortgage loans held-for-sale65 — 7 — 
Total mortgage loans$55,140 100.0 %$55,870 100.0 %

The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($641) million and ($716) million at September 30, 2026 and December 31, 2025, respectively. The accrued interest income for commercial, agricultural and residential mortgage loans at September 30, 2026 was $101 million, $146 million and $130 million, respectively. The accrued interest income for commercial, agricultural and residential mortgage loans at December 31, 2025 was $110 million, $159 million and $103 million, respectively. The accrued interest income related to mortgage loans is included in accrued investment income on the interim condensed consolidated balance sheets.

Purchases of mortgage loans, consisting primarily of residential mortgage loans, from unaffiliated parties, were $1.8 billion and $3.8 billion for the three months and nine months ended September 30, 2026, respectively, and $414 million and $1.5 billion for the three months and nine months ended September 30, 2025, respectively.

Sales of mortgage loans were $0 and $25 million for the three months and nine months ended September 30, 2026, respectively.

For the nine months ended September 30, 2025, the Company exchanged, as part of loan restructurings, commercial mortgage loans with an amortized cost of $52 million for equity interests in REJVs.

For the three months and nine months ended September 30, 2026, the Company acquired wholly-owned real estate by completing foreclosures on commercial mortgage loans with an amortized cost of $0 and $56 million, respectively.

Rollforward of ACL for Mortgage Loans by Portfolio Segment

The rollforward of ACL for mortgage loans, by portfolio segment, was as follows:

Nine Months Ended September 30,
20262025
CommercialAgriculturalResidentialTotalCommercialAgriculturalResidentialTotal
(In millions)
Balance, beginning of period$436 $81 $184 $701 $312 $63 $128 $503 
Provision (release)313 14 (7)320 307 15 22 344 

Charge-offs, net of recoveries

(124)(11)(2)(137)(100)(7)— (107)
Balance, end of period$625 $84 $175 $884 $519 $71 $150 $740 

31


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

The gross charge-offs of mortgage loans by origination year and portfolio segment for the nine months ended September 30, 2026 were as follows:

Portfolio Segment20262025202420232022PriorTotal
(In millions)
Commercial$— $— $— $— $8 $116 $124 
Agricultural— — — — — 11 11 
Residential— — — — 1 1 2 
Total$— $— $— $— $9 $128 $137 

ACL Methodology

The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses).

32


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Commercial and Agricultural Mortgage Loan Portfolio Segments

Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. In its evaluation, the Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for such loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans.

Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans.

For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio.

For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated.

33


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

After commercial and agricultural mortgage loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that is not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly.

Residential Mortgage Loan Portfolio Segment

The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year.

For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss.

Modifications to Borrowers Experiencing Financial Difficulty

The Company may modify mortgage loans to borrowers. Each mortgage loan modification is evaluated to determine whether the borrower was experiencing financial difficulties. Disclosed below are those modifications, in materially impacted mortgage segments, where the borrower was determined to be experiencing financial difficulties and the mortgage loans were modified by any of the following means: principal forgiveness, interest rate reduction, other-than-insignificant payment delay or maturity extension. The amount, timing and extent of modifications granted and subsequent performance are considered in determining any ACL recorded. All loans modified to borrowers experiencing financial difficulties are evaluated individually for credit loss as collateral dependent loans.

34


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

These mortgage loan modifications are summarized as follows:

Three Months Ended September 30,
2026
Amortized CostAffected Loans
(in Years)
Portfolio SegmentMaturity
Extension
Payment
Delay
TotalWeighted-Average
 Life Increase
Average Years
Payment Deferral
% of Book
Value
(Dollars in millions)
Commercial$— $— $— — — — %
Agricultural— — — — — — %
Total$— $— $— 
Three Months Ended September 30,
2025
Amortized CostAffected Loans
(in Years)
Portfolio SegmentMaturity
Extension
Payment
Delay
TotalWeighted-Average
 Life Increase
Average Years Payment Deferral% of Book
Value
(Dollars in millions)
Commercial$208 $— $208 Less than one year— <1%
Agricultural— 126 126 — 2 years<1%
Total$208 $126 $334 
Nine Months Ended September 30,
2026
Amortized CostAffected Loans
(in Years)
Portfolio SegmentMaturity
Extension
Payment
Delay
TotalWeighted-Average
 Life Increase
Average Years Payment Deferral% of Book
Value
(Dollars in millions)
Commercial$230 $— $230 2 years— <1%
Agricultural— — — — — — %
Total$230 $— $230 
Nine Months Ended September 30,
2025
Amortized CostAffected Loans
(in Years)
Portfolio SegmentMaturity
Extension
Payment
Delay
TotalWeighted-Average
 Life Increase
Average Years Payment Deferral% of Book
Value
(Dollars in millions)
Commercial$668 $— $668 4 years— 2.2 %
Agricultural— 126 126 — 2 years<1%
Total$668 $126 $794 

For the three months and nine months ended September 30, 2026 and 2025, all commercial mortgage loans modified within the past 12 months to borrowers experiencing financial difficulties and still outstanding were current.

35


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Credit Quality of Mortgage Loans by Portfolio Segment

The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2026:

Credit Quality Indicator20262025202420232022PriorRevolving
Loans
Total% of
Total

(Dollars in millions)

LTV ratios:

Less than 65%$1,166 $1,465 $1,761 $1,172 $870 $7,191 $1,425 $15,050 56.9 %
65% to 75%352 276 292 247 1,240 1,752 — 4,159 15.7 
76% to 80%— 52 — 108 273 972 — 1,405 5.3 
Greater than 80%1 133 182 — 427 5,116 — 5,859 22.1 
Total$1,519 $1,926 $2,235 $1,527 $2,810 $15,031 $1,425 $26,473 100.0 %

DSCR:

> 1.20x$1,392 $1,659 $1,820 $1,198 $2,149 $13,093 $1,425 $22,736 85.9 %

1.00x - 1.20x

83 248 — 246 218 937 — 1,732 6.5 
<1.00x44 19 415 83 443 1,001 — 2,005 7.6 
Total$1,519 $1,926 $2,235 $1,527 $2,810 $15,031 $1,425 $26,473 100.0 %

The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2026:

Credit Quality Indicator20262025202420232022PriorRevolving
Loans
Total% of
Total
(Dollars in millions)
LTV ratios:
Less than 65%$1,080 $904 $498 $670 $1,498 $8,156 $1,146 $13,952 91.9 %
65% to 75%52 59 32 73 184 567 54 1,021 6.7 
76% to 80%— — — — — 11 — 11 0.1 
Greater than 80%17 — — 18 109 44 13 201 1.3 
Total$1,149 $963 $530 $761 $1,791 $8,778 $1,213 $15,185 100.0 %

The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2026:

Credit Quality Indicator20262025202420232022PriorRevolving
Loans
Total% of
Total
(Dollars in millions)
Performance indicators:
Performing$2,345 $2,314 $1,147 $209 $1,458 $6,452 $— $13,925 97.4 %
Nonperforming (1)11 39 50 18 60 198 — 376 2.6 

Total

$2,356 $2,353 $1,197 $227 $1,518 $6,650 $— $14,301 100.0 %

__________________

(1)Includes residential mortgage loans in process of foreclosure with an amortized cost of $155 million and $143 million at September 30, 2026 and December 31, 2025, respectively.

36


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Past Due and Nonaccrual Mortgage Loans

The Company has a high quality, well performing mortgage loan portfolio, with 98% of all mortgage loans classified as performing at both September 30, 2026 and December 31, 2025. The Company defines delinquency in a manner consistent with industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows:

Past DuePast Due
and Still Accruing Interest
Nonaccrual
Portfolio SegmentSeptember 30, 2026December 31, 2025September 30, 2026December 31, 2025September 30, 2026December 31, 2025
(In millions)
Commercial$389 $339 $— $— $714 $945 
Agricultural168 172 25 43 178 165 
Residential376 365 — — 376 365 
Total$933 $876 $25 $43 $1,268 $1,475 

Real Estate and REJVs

The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method REJVs. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated:

September 30, 2026December 31, 2025Three Months 
 Ended 
 September 30,
Nine Months
Ended
September 30,
2026202520262025
Income TypeCarrying ValueIncome
(In millions)
Wholly-owned real estate:
Leased real estate$1,518 $1,331 $52 $44 $145 $126 
Other real estate615 553 92 82 255 246 
REJVs6,359 6,914 42 (1)132 52 
Total real estate and REJVs$8,492 $8,798 $186 $125 $532 $424 

Depreciation expense on real estate investments was $24 million and $75 million for the three months and nine months ended September 30, 2026, respectively, and $23 million and $66 million for the three months and nine months ended September 30, 2025, respectively. Real estate investments were net of accumulated depreciation of $863 million and $783 million at September 30, 2026 and December 31, 2025, respectively.

Leased Real Estate Investments — Operating Leases

The Company, as lessor, leases investment real estate, principally commercial real estate for office, apartment and retail use, through a variety of operating lease arrangements, which typically include tenant reimbursement for property operating costs and options to renew or extend the lease. In some circumstances, leases may include an option for the lessee to purchase the property. In addition, certain leases of retail space may stipulate that a portion of the income earned is contingent upon the level of the tenants’ revenues. The Company has elected a practical expedient of not separating non-lease components related to reimbursement of property operating costs from associated lease components. These property operating costs have the same timing and pattern of transfer as the related lease component, because they are incurred over the same period of time as the operating lease. Therefore, the combined component is accounted for as a single operating lease. Risk is managed through lessee credit analysis, property type diversification and geographic diversification.

See Note 10 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for a summary of leased real estate investments and earned income by property type.

37


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Other Invested Assets

Tax Equity Investments

The Company invests in certain tax equity investments, including low income housing tax credit partnerships and renewable energy partnerships. The carrying value of tax equity investments, reported in other invested assets on the interim condensed consolidated balance sheets, was $1.1 billion and $676 million at September 30, 2026 and December 31, 2025, respectively. For the three months and nine months ended September 30, 2026, income tax credits and other income tax benefits of $30 million and $87 million, respectively, and amortized expenses of $25 million and $74 million, respectively, were recognized net as a component of income tax expense on the Company’s interim condensed consolidated statements of operations. For the three months and nine months ended September 30, 2025, income tax credits and other income tax benefits of $38 million and $98 million, respectively, and amortized expenses of $30 million and $87 million, respectively, were recognized net as a component of income tax expense on the Company’s interim condensed consolidated statements of operations.

FVO Securities and Equity Securities

The following table presents FVO securities and equity securities by asset type.

September 30, 2026December 31, 2025
Net Unrealized Gains (Losses) (1)Estimated Fair ValueCostNet Unrealized Gains (Losses) (1)Estimated Fair Value
Asset TypeCost
(In millions)
FVO securities
Securities held by collateralized financing entities (“CFEs”)$833 $(12)$821 $— $— $— 
General account and other securities260 847 1,107 218 648 866 
Total FVO securities$1,093 $835 $1,928 $218 $648 $866 
Equity securities
Common stock (2)$171 $27 $198 $170 $25 $195 
Non-redeemable preferred stock38 (11)27 37 7 44 
Total equity securities$209 $16 $225 $207 $32 $239 

__________________

(1)Represents cumulative changes in estimated fair value, recognized in earnings.

(2)Includes common stock and certain mutual funds.

Cash Equivalents

Cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was $4.0 billion and $5.0 billion, at estimated fair value, at September 30, 2026 and December 31, 2025, respectively.

Concentrations of Credit Risk

There were no investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at estimated fair value, at both September 30, 2026 and December 31, 2025.

38


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Securities Lending Transactions and Repurchase Agreements

Securities, Collateral and Reinvestment Portfolio

Transactions and agreements accounted for as secured borrowings were as follows:

September 30, 2026December 31, 2025
Securities (1)Securities (1)
Agreement TypeEstimated Fair ValueCash Collateral Received from Counterparties (2)Reinvestment Portfolio at Estimated
Fair Value
Estimated Fair ValueCash Collateral Received from Counterparties (2)Reinvestment Portfolio at Estimated
Fair Value
(In millions)
Securities lending$7,803 $8,029 $7,921 $6,840 $7,043 $6,979 
Repurchase agreements$3,513 $3,475 $3,428 $3,002 $2,975 $2,948 

__________________

(1)These securities were included within fixed maturity securities AFS, short-term investments and cash equivalents at both September 30, 2026 and December 31, 2025. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge these securities.

(2)The liability for cash collateral is included within payables for collateral under securities loaned and other transactions.

Contractual Maturities

Contractual maturities of transactions and agreements accounted for as secured borrowings were as follows:

September 30, 2026December 31, 2025
Remaining MaturitiesRemaining Maturities
Cash collateral liability by security type:Open (1)1 Month
or Less
Over 1
 Month to 6
Months
Over 6 
Months
 to 1 Year
TotalOpen (1)1 Month
or Less
Over 1
Month to 6
Months
Over 6 Months to 1 YearTotal
(In millions)
Securities lending:
U.S. government and agency$1,746 $3,716 $2,567 $— $8,029 $971 $2,445 $3,627 $— $7,043 
Repurchase agreements:
U.S. government and agency$— $3,475 $— $— $3,475 $— $2,975 $— $— $2,975 

__________________

(1)The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.

If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell investments to meet the return obligation, it may have difficulty selling such collateral that is invested in a timely manner, be forced to sell investments in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both.

The securities lending and repurchase agreement reinvestment portfolios consist principally of high quality, liquid, publicly traded fixed maturity securities AFS, short-term investments, cash equivalents or cash. If the securities in the reinvestment portfolio become less liquid, liquidity resources within the general account are available to meet any potential cash demands when securities are put back by the counterparty.

39


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Invested Assets on Deposit, Held in Trust and Pledged as Collateral

Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value, and were as follows at:

September 30, 2026December 31, 2025
(In millions)
Invested assets on deposit (regulatory deposits)$103 $106 
Invested assets held in trust (external reinsurance agreements)1,461 285 
Invested assets pledged as collateral (1)23,239 21,380 
Total invested assets on deposit, held in trust and pledged as collateral$24,803 $21,771 

__________________

(1)The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements and secured debt (see Notes 4 and 14 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report). For information regarding invested assets pledged in connection with derivative transactions, see Note 9.

See “— Securities Lending Transactions and Repurchase Agreements” for information regarding securities supporting securities lending transactions and repurchase agreements. In addition, the Company’s investment in Federal Home Loan Bank of New York common stock, included within other invested assets, which is considered restricted until redeemed by the issuer, was $628 million at redemption value at both September 30, 2026 and December 31, 2025.

The Company maintained invested assets and cash and cash equivalents that are subject to ceded reinsurance arrangements with third parties of $7.0 billion and $8.2 billion at September 30, 2026 and December 31, 2025, respectively, which includes cash and cash equivalents of $113 million and $1.0 billion at September 30, 2026 and December 31, 2025, respectively.

Variable Interest Entities

The Company has invested in legal entities that are VIEs. Legal entities are determined to be VIEs if (1) the equity investors lack (i) the ability to control the entity, (ii) the obligation to absorb losses or (iii) the right to receive returns of the entity, or (2) the entity lacks sufficient equity to finance its activities without subordinated financial support.

For VIEs, the Company determines whether it is the primary beneficiary, which involves an evaluation of the purpose and design of the entity and, whether based on the design of the entity, the Company has both (1) the power to direct the activities of the entity which most significantly affect the economic performance of the entity and (2) the obligation to absorb losses or the right to receive benefits that are potentially significant to the VIE. Significant judgment is required in the primary beneficiary determination, which includes an evaluation of the substance of contractual arrangements and voting agreements, the rights of other investors in an entity and the potential financial results of the entity.

The Company continuously assesses if facts or circumstances indicate that a potential change in the primary beneficiary has occurred. This could include new contractual arrangements of an entity or changes in the investors of an entity. As a result of changes in circumstances, the Company may consolidate or deconsolidate a VIE.

Consolidated VIEs

The Company is the primary beneficiary of certain CFEs, primarily collateralized loan obligations (“CLOs”), investment funds and partnership entities in which the Company has invested, which requires the Company to consolidate them as VIEs. The assets of the VIEs may only be used to satisfy the liabilities of the respective VIEs. The Company is not required to provide, and has not provided, material financial support to the VIEs, other than its investment in these VIEs.

40


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

The table below reflects the carrying amount and balance sheet classification in which the assets and liabilities of consolidated VIEs are reported. The liabilities primarily comprise debt instruments issued by the VIEs. The creditors of these VIEs do not have recourse to the Company in excess of the assets contained within the respective VIEs.

September 30, 2026December 31, 2025
Instrument TypeConsolidated VIEs
(In millions)
FVO securities primarily held by CFEs (1)$821 $— 
Mortgage loans132180
Real estate and REJVs2,466 2,435 
Renewable energy partnership (1)38 45 
Cash and cash equivalents119 8 
Other30 6 
Total assets of consolidated VIEs$3,606 $2,674 
Notes issued by CFEs (2)$803 $— 
Other liabilities75 9 
Total liabilities of consolidated VIEs$878 $9 

__________________

(1)Included in other invested assets.

(2)In the first quarter of 2026, beneficial interests in CFEs were transferred to the Company from an affiliate, which resulted in the Company, as the primary beneficiary, consolidating the CFEs as VIEs. Notes issued by CFEs represent notes issued by CLOs. The creditors of these consolidated VIEs do not have recourse to the Company in excess of the assets contained within the VIEs. For these notes, the Company has elected the FVO and has based the estimated fair value on the more observable of the notes or the corresponding assets. Changes in estimated fair value are reported in net investment gains (losses).

Unconsolidated VIEs

The Company has determined that it is not the primary beneficiary of certain VIEs because the Company does not have both (1) the power to direct the activities of the entity which most significantly affect the economic performance of the entity and (2) the obligation to absorb losses or the right to receive benefits that are potentially significant to the VIE.

The Company invests in structured products issued by CFEs or securitization entities that are VIEs which typically do not have substantial equity. Its investments in these structured products are fixed maturity securities investments and include mortgage-backed securities, and ABS & CLOs. The Company’s exposure to losses of these entities is limited to the amount of its investment. See “— Fixed Maturity Securities Available-for-Sale” for details regarding amounts and classification of these assets.

The Company also invests in or provides loans to other legal entities that are VIEs. These primarily include hedge funds, private equity funds and similar entities that are classified within OLPIs, REJVs, other invested assets, fixed maturity securities and mortgage loans. The Company’s maximum exposure to loss for these VIEs is limited to the carrying value of the equity investment plus any unfunded capital commitments. The carrying value of these investments was $12.1 billion and $12.0 billion at September 30, 2026 and December 31, 2025, respectively, and the Company’s unfunded commitments were $2.6 billion and $2.3 billion at September 30, 2026 and December 31, 2025, respectively.

The Company did not provide financial or other support that it was not contractually obligated to provide to entities designated as VIEs for the nine months ended September 30, 2026 or 2025.

41


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Net Investment Income

The composition of net investment income by asset type was as follows:

Three Months 
 Ended 
 September 30,
Nine Months
Ended
September 30,
Asset Type2026202520262025
(In millions)
Fixed maturity securities AFS$2,138 $1,922 $6,298 $5,687 
Mortgage loans721 749 2,150 2,255 
Policy loans71 75 216 216 

Real estate and REJVs

186 125 532 424 
OLPI253 222 432 362 
Cash, cash equivalents and short-term investments95 75 268 244 
FVO securities37 68 138 116 
Operating joint venture56 84 124 132 
Equity securities— 1 2 5 
Other116 7 305 180 
Subtotal investment income3,673 3,328 10,465 9,621 
Less: Investment expenses359 397 1,037 1,008 

Net investment income

$3,314 $2,931 $9,428 $8,613 
Net Investment Income Information
Net realized and unrealized gains (losses) recognized in net investment income:
Net realized gains (losses) from sales and disposals$— $— $— $— 

Net unrealized gains (losses) from changes in estimated fair value (primarily FVO securities and REJVs)

32 70 131 140 
Net realized and unrealized gains (losses) recognized in net investment income$32 $70 $131 $140 
Changes in estimated fair value subsequent to purchase of FVO securities still held at the end of the respective periods and recognized in net investment income$20 $68 $105 $114 

Equity method investments net investment income (primarily REJVs, OLPI, tax credit and renewable energy partnerships and an operating joint venture)

$374 $331 $730 $582 

Net Investment Gains (Losses)

Net Investment Gains (Losses) by Instrument Type and Transaction Type

The composition of net investment gains (losses) by instrument type and transaction type was as follows:

42


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

Three Months 
 Ended 
 September 30,
Nine Months
Ended
September 30,
Instrument Type2026202520262025
(In millions)
Fixed maturity securities AFS$(180)$(169)$(412)$(395)

Mortgage loans

(133)(13)(339)(353)

Real estate and REJVs (excluding changes in estimated fair value)

4 6 (165)8 

OLPI (excluding changes in estimated fair value) (1)

(12)5 (49)25 
Equity securities(22)(14)(14)(7)

FVO securities

(18)— (36)— 

Notes issued by CFEs

14 — 12 — 

Other gains (losses)

24 (21)29 (21)
Subtotal (323)(206)(974)(743)

Change in estimated fair value of OLPI and REJVs

1 (1)5 (1)
Non-investment portfolio gains (losses)6 (9)21 (79)
Subtotal 7 (10)26 (80)

Net investment gains (losses)

$(316)$(216)$(948)$(823)
Transaction Type

Realized gains (losses) on investments sold or disposed (1)

$(164)$(65)$(490)$(316)

Impairment (losses)

(20)(18)(189)(23)
Recognized gains (losses):

Change in ACL recognized in earnings

(97)(107)(246)(430)
Unrealized net gains (losses) recognized in earnings(41)(17)(44)25 
Total recognized gains (losses)(138)(124)(290)(405)
Non-investment portfolio gains (losses)6 (9)21 (79)
Net investment gains (losses)$(316)$(216)$(948)$(823)
Net Investment Gains (Losses) Information
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)$(18)$(15)$(13)$(5)
Changes in estimated fair value subsequent to purchase of FVO securities still held at the end of the respective periods and recognized in net investment gains (losses)$— $— $(15)$— 
Changes in estimated fair value subsequent to recognition of Notes issued by CFEs still outstanding at the end of the respective periods and recognized in net investment gains (losses)$14 $— $12 $— 
Other gains (losses) include:
Gains (losses) on disposed investments which were previously in a qualified cash flow hedging relationship$1 $(26)$(9)$(17)
Gains (losses) on leveraged leases and renewable energy partnerships$9 $— $29 $— 
Foreign currency gains (losses)$20 $1 $38 $(75)
Net Realized Investment Gains (Losses) From Sales and Disposals of Investments:
Recognized in net investment gains (losses)$(164)$(65)$(490)$(316)
Recognized in net investment income— — — — 
Net realized investment gains (losses) from sales and disposals of investments$(164)$(65)$(490)$(316)

__________________

43


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

8. Investments (continued)

(1)    Includes a net loss of $40 million and $1 million for the nine months ended September 30, 2026 and 2025, respectively, for private equity investments sold. For the nine months ended September 30, 2026 and 2025, the Company sold $577 million and $36 million, respectively, in portfolios of investments to funds for proceeds of $537 million and $35 million, respectively, in cash and receivables secured by the value of the respective funds. An affiliate has entered into agreements to serve as the asset manager of the funds for which it receives management fees.

Fixed Maturity Securities AFS and Equity Securities — Composition of Net Investment Gains (Losses)

The composition of net investment gains (losses) for these securities was as follows:

Three Months 
 Ended 
 September 30,
Nine Months
Ended
September 30,
Fixed Maturity Securities AFS2026202520262025
(In millions)
Proceeds$4,751 $3,761 $18,535 $9,843 
Gross investment gains$32 $59 $155 $100 
Gross investment (losses)(240)(135)(628)(406)
Realized gains (losses) on sales and disposals(208)(76)(473)(306)
Net credit loss (provision) release (change in ACL recognized in earnings)28 (93)64 (84)
Impairment (losses)— — (3)(5)
Net credit loss (provision) release and impairment (losses)28 (93)61 (89)
Net investment gains (losses)$(180)$(169)$(412)$(395)

Equity Securities

Realized gains (losses) on sales and disposals$14 $2 $5 $(32)
Unrealized net gains (losses) recognized in earnings(36)(16)(19)25 
Net investment gains (losses)$(22)$(14)$(14)$(7)

Related Party Investment Transactions

The Company transfers invested assets primarily consisting of fixed maturity securities AFS, mortgage loans, real estate and REJVs, and FVO securities to and from affiliates. Invested assets transferred to and from affiliates were as follows:

Three Months
Ended
September 30,
Nine Months
Ended
September 30,
2026202520262025
(In millions)
Estimated fair value of invested assets transferred to affiliates$— $— $498 $21 
Amortized cost of invested assets transferred to affiliates$— $— $525 $20 
Net investment gains (losses) recognized on transfers$— $— $(27)$1 
Estimated fair value of invested assets transferred from affiliates$91 $— $455 $70 

Recurring related party investments were as follows at:

September 30, 2026December 31, 2025
Investment Type/
Balance Sheet Category
Related PartyCarrying Value
(In millions)
Affiliated investments (1)

MetLife, Inc.

$1,014 $1,016 

Affiliated investments (2)

Metropolitan General Insurance Company152 152 

Affiliated funds withheld (3)

Metropolitan Tower Life Insurance Company (“MTL”)

2,223 2,476 
Other invested assets$3,389 $3,644 

________________

(1)Represents an investment in affiliated senior unsecured notes which have maturity dates from December 2028 to July 2033 and bear interest, payable semi-annually, at rates per annum ranging from 1.72% to 4.30%. In July 2026, ¥23.8 billion (the equivalent of $147 million) of 1.61% and 1.64% affiliated senior unsecured notes matured and were refinanced with ¥23.8 billion in affiliated senior unsecured notes which mature in July 2033 and bear interest, payable semi-annually, at rates per annum ranging from 4.29% to 4.30%. These affiliated investments earned investment income of $9 million and $22 million for the three months and nine months ended September 30, 2026, respectively, and $5 million and $15 million for the three months and nine months ended September 30, 2025, respectively.

(2)Represents an investment in the affiliate’s unsecured note which matures December 2034 and bears interest, payable semi-annually, at a rate per annum of 6.47%.

(3)Represents affiliated funds withheld, reported in other invested assets, related to an agreement the Company, through its wholly-owned subsidiary, entered into to assume certain group annuity contracts issued in connection with a qualifying pension risk transfer on a modified coinsurance basis from MTL.

The Company paid asset management fees to an affiliate of $112 million and $333 million for the three months and nine months ended September 30, 2026, respectively, and $105 million and $319 million for the three months and nine months ended September 30, 2025, respectively.

See “— Variable Interest Entities” for information on investments in affiliated REJVs, affiliated mortgage loans and affiliated investment funds.

9. Derivatives

Accounting for Derivatives

See Note 1 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for a description of the Company’s accounting policies for derivatives and Note 10 for information about the fair value hierarchy for derivatives.

Types of Derivative Instruments and Derivative Strategies

The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Commonly used derivative instruments include, but are not limited to:

•Interest rate derivatives: swaps, total return swaps, caps, floors, futures, swaptions, forwards and synthetic GICs;

•Foreign currency exchange rate derivatives: swaps and forwards;

•Credit derivatives: purchased or written single name or index credit default swaps, and forwards; and

•Equity derivatives: index options, variance swaps, exchange-traded futures and total return swaps.

For detailed information on these contracts and the related strategies, see Note 11 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report.

44


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

Primary Risks Managed by Derivatives

The following table presents the primary underlying risk exposure, gross notional amount, and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at:

September 30, 2026December 31, 2025
Primary Underlying Risk ExposureEstimated Fair ValueGross
Notional
Amount
Estimated Fair Value

Gross

Notional

Amount

AssetsLiabilitiesAssetsLiabilities
(In millions)
Derivatives Designated as Hedging Instruments:
Fair value hedges:
Interest rate swapsInterest rate$4,233 $838 $776 $4,446 $923 $667 
Foreign currency swapsForeign currency exchange rate3,978 34 51 959 33 8 
Subtotal8,211 872 827 5,405 956 675 
Cash flow hedges:
Interest rate swapsInterest rate5,107 — 280 3,337 — 249 
Foreign currency swapsForeign currency exchange rate34,309 1,806 695 34,771 2,276 896 
Subtotal39,416 1,806 975 38,108 2,276 1,145 
Net investment in a foreign operation (“NIFO”) hedges:
Foreign currency forwardsForeign currency exchange rate54 — 2 — — — 
Subtotal54 — 2 — — — 
Total qualifying hedges47,681 2,678 1,804 43,513 3,232 1,820 
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Interest rate swapsInterest rate12,384 1,139 812 13,092 1,403 614 
Interest rate floorsInterest rate4,890 18 — 5,390 30 — 
Interest rate capsInterest rate13,200 154 — 12,950 46 — 
Interest rate futuresInterest rate108 — — 90 — — 
Interest rate optionsInterest rate19,060 178 185 20,368 99 85 
Synthetic GICsInterest rate3,170 — — 3,156 — — 
Foreign currency swapsForeign currency exchange rate4,064 209 70 3,770 240 106 
Foreign currency forwardsForeign currency exchange rate1,049 19 3 2,859 5 18 
Credit default swaps — purchasedCredit576 1 4 685 2 5 
Credit default swaps — writtenCredit12,930 145 1 6,619 101 1 
Equity futuresEquity market163 — — 393 3 — 
Equity index optionsEquity market15,839 596 354 15,032 220 232 
Equity variance swapsEquity market4 — — 5 — — 
Equity total return swapsEquity market1,380 29 25 2,413 7 34 
Total non-designated or nonqualifying derivatives88,817 2,488 1,454 86,822 2,156 1,095 
Total$136,498 $5,166 $3,258 $130,335 $5,388 $2,915 

Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship at either September 30, 2026 or December 31, 2025. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge MRBs that do not qualify for hedge accounting because the changes in estimated fair value of the MRBs are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged.

45


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, nonqualifying hedging relationships and embedded derivatives:

Three Months Ended September 30, 2026
Net
Investment
Income
Net
Investment
Gains
(Losses)
Net
Derivative
Gains
(Losses)
Policyholder
Benefits and
Claims

Interest Credited to PABs

OCI

(In millions)
Gain (Loss) on Fair Value Hedges:
Interest rate derivatives:
Derivatives designated as hedging instruments (1)$1 $— N/A$(187)$(62)N/A
Hedged items(1)— N/A182 62 N/A
Foreign currency exchange rate derivatives:
Derivatives designated as hedging instruments (1)2 (6)N/A— 3 N/A
Hedged items(2)5 N/A— (4)N/A
Amount excluded from the assessment of hedge effectiveness— — N/A— — $(50)
Subtotal— (1)N/A(5)(1)(50)
Gain (Loss) on Cash Flow Hedges:
Interest rate derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A(282)
Amount of gains (losses) reclassified from AOCI into income— 1 $— — — (1)

Foreign currency exchange rate derivatives: (1)

Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A(254)
Amount of gains (losses) reclassified from AOCI into income— (92)— — — 92 
Foreign currency transaction gains (losses) on hedged items— 108 — — — — 
Credit derivatives: (1)
Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A— 

Amount of gains (losses) reclassified from AOCI into income

— — — — — — 

Subtotal

— 17 — — — (445)

Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:

Interest rate derivatives (1)— N/A(175)N/AN/AN/A
Foreign currency exchange rate derivatives (1)— N/A(20)N/AN/AN/A
Credit derivatives — purchased (1)— N/A— N/AN/AN/A
Credit derivatives — written (1)— N/A(22)N/AN/AN/A
Equity derivatives (1)(6)N/A(15)N/AN/AN/A
Foreign currency transaction gains (losses) on hedged items— N/A(27)N/AN/AN/A
Subtotal(6)N/A(259)N/AN/AN/A
Earned income on derivatives79 — 25 6 (35)— 

Synthetic GICs

N/AN/A1 N/AN/AN/A

Embedded derivatives

N/AN/A839 N/AN/AN/A
Total$73 $16 $606 $1 $(36)$(495)

46


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

Three Months Ended September 30, 2025
Net Investment IncomeNet Investment Gains (Losses)Net Derivative Gains (Losses)Policyholder Benefits and Claims

Interest Credited to PABs

OCI

(In millions)

Gain (Loss) on Fair Value Hedges:

Interest rate derivatives:

Derivatives designated as hedging instruments (1)

$— $— N/A$6 $2 N/A

Hedged items

— — N/A(10)(2)N/A

Foreign currency exchange rate derivatives:

Derivatives designated as hedging instruments (1)

2 — N/A— (4)N/A

Hedged items

(3)— N/A— 3 N/A

Subtotal

(1)— N/A(4)(1)N/A
Gain (Loss) on Cash Flow Hedges:

Interest rate derivatives: (1)

Amount of gains (losses) deferred in AOCI

N/AN/AN/AN/AN/A$(5)

Amount of gains (losses) reclassified from AOCI into income

4 (26)$— — — 22 
Foreign currency exchange rate derivatives: (1)

Amount of gains (losses) deferred in AOCI

N/AN/AN/AN/AN/A120 

Amount of gains (losses) reclassified from AOCI into income

1 (87)— — — 86 

Foreign currency transaction gains (losses) on hedged items

— 88 — — — — 

Credit derivatives: (1)

Amount of gains (losses) deferred in AOCI

N/AN/AN/AN/AN/A— 
Amount of gains (losses) reclassified from AOCI into income— — — — — — 

Subtotal

5 (25)— — — 223 

Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:

Interest rate derivatives (1)

— N/A(57)N/AN/AN/A

Foreign currency exchange rate derivatives (1)

— N/A66 N/AN/AN/A

Credit derivatives — purchased (1)

— N/A(6)N/AN/AN/A

Credit derivatives — written (1)

— N/A— N/AN/AN/A

Equity derivatives (1)

(23)N/A(276)N/AN/AN/A

Foreign currency transaction gains (losses) on hedged items

— N/A(30)N/AN/AN/A

Subtotal

(23)N/A(303)N/AN/AN/A

Earned income on derivatives

18 — 57 1 (38)— 
Synthetic GICsN/AN/A2 N/AN/AN/A
Embedded derivativesN/AN/A(159)N/AN/AN/A

Total

$(1)$(25)$(403)$(3)$(39)$223 

47


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

Nine Months Ended September 30, 2026
Net
Investment
Income
Net
Investment
Gains
(Losses)
Net
Derivative
Gains
(Losses)
Policyholder
Benefits and
Claims

Interest Credited to PABs

OCI

(In millions)

Gain (Loss) on Fair Value Hedges:

Interest rate derivatives:

Derivatives designated as hedging instruments (1)

$1 $— N/A$(226)$(99)N/A

Hedged items

(1)— N/A212 98 N/A

Foreign currency exchange rate derivatives:

Derivatives designated as hedging instruments (1)

54 (8)N/A— (5)N/A

Hedged items

(54)6 N/A— 6 

N/A

Amount excluded from the assessment of hedge effectiveness— — N/A— — $(82)

Subtotal

— (2)N/A(14)— (82)
Gain (Loss) on Cash Flow Hedges:

Interest rate derivatives: (1)

Amount of gains (losses) deferred in AOCI

N/AN/AN/AN/AN/A(301)

Amount of gains (losses) reclassified from AOCI into income

2 (9)$— — — 7 
Foreign currency exchange rate derivatives: (1)

Amount of gains (losses) deferred in AOCI

N/AN/AN/AN/AN/A(228)

Amount of gains (losses) reclassified from AOCI into income

2 (352)— — — 350 

Foreign currency transaction gains (losses) on hedged items

— 368 — — — — 

Credit derivatives: (1)

Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A— 
Amount of gains (losses) reclassified from AOCI into income— — — — — — 

Subtotal

4 7 — — — (172)

Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:

Interest rate derivatives (1)

— N/A(169)N/AN/AN/A

Foreign currency exchange rate derivatives (1)

— N/A55 N/AN/AN/A

Credit derivatives — purchased (1)

— N/A(2)N/AN/AN/A

Credit derivatives — written (1)

— N/A(24)N/AN/AN/A

Equity derivatives (1)

(38)N/A(265)N/AN/AN/A

Foreign currency transaction gains (losses) on hedged items

— N/A(49)N/AN/AN/A

Subtotal

(38)N/A(454)N/AN/AN/A

Earned income on derivatives

159 — 136 20 (109)— 
Synthetic GICsN/AN/A3 N/AN/AN/A
Embedded derivativesN/AN/A1,014 N/AN/AN/A

Total

$125 $5 $699 $6 $(109)$(254)

48


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

Nine Months Ended September 30, 2025
Net Investment IncomeNet Investment Gains (Losses)Net Derivative Gains (Losses)Policyholder Benefits and Claims

Interest Credited to PABs

OCI
(In millions)

Gain (Loss) on Fair Value Hedges:

Interest rate derivatives:

Derivatives designated as hedging instruments (1)

$— $— N/A$83 $48 N/A

Hedged items

— — N/A(97)(47)N/A

Foreign currency exchange rate derivatives:

Derivatives designated as hedging instruments (1)

(25)— N/A— 119 N/A

Hedged items

23 — N/A— (120)N/A

Subtotal

(2)— N/A(14)— N/A
Gain (Loss) on Cash Flow Hedges:

Interest rate derivatives: (1)

Amount of gains (losses) deferred in AOCI

N/AN/AN/AN/AN/A$30 

Amount of gains (losses) reclassified from AOCI into income

30 (17)$— — — (13)
Foreign currency exchange rate derivatives: (1)

Amount of gains (losses) deferred in AOCI

N/AN/AN/AN/AN/A132 

Amount of gains (losses) reclassified from AOCI into income

3 1,331 — — — (1,334)

Foreign currency transaction gains (losses) on hedged items

— (1,337)— — — — 

Credit derivatives: (1)

Amount of gains (losses) deferred in AOCIN/AN/AN/AN/AN/A— 
Amount of gains (losses) reclassified from AOCI into income— — — — — — 

Subtotal

33 (23)— — — (1,185)

Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments:

Interest rate derivatives (1)

— N/A(71)N/AN/AN/A

Foreign currency exchange rate derivatives (1)

— N/A(406)N/AN/AN/A

Credit derivatives — purchased (1)

— N/A(18)N/AN/AN/A

Credit derivatives — written (1)

— N/A10 N/AN/AN/A

Equity derivatives (1)

(34)N/A(496)N/AN/AN/A

Foreign currency transaction gains (losses) on hedged items

— N/A164 N/AN/AN/A

Subtotal

(34)N/A(817)N/AN/AN/A

Earned income on derivatives

108 — 165 5 (109)— 
Synthetic GICsN/AN/A6 N/AN/AN/A
Embedded derivativesN/AN/A(387)N/AN/AN/A

Total

$105 $(23)$(1,033)$(9)$(109)$(1,185)

__________________

(1)Excludes earned income on derivatives.

Fair Value Hedges

The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, and (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities.

49


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

The following table presents the balance sheet classification, carrying amount and cumulative fair value of hedging adjustments for items designated and qualifying as hedged items in fair value hedges:

September 30, 2026December 31, 2025September 30, 2026December 31, 2025
Balance Sheet Line ItemCarrying Amount of the
Hedged
Assets/(Liabilities)
Cumulative Amount
of Fair Value Hedging Adjustments
Included in the Carrying Amount of Hedged
Assets/(Liabilities) (1)
(In millions)
Fixed maturity securities AFS$3,664 $120 $— $— 

FPBs

$(2,124)$(2,509)$543 $319 

PABs

$(2,251)$(2,498)$192 $(35)

__________________

(1)Includes ($51) million and ($73) million of hedging adjustments on discontinued hedging relationships at September 30, 2026 and December 31, 2025, respectively.

For certain foreign currency swaps, changes in estimated fair value related to cross-currency basis spreads are excluded from the effectiveness assessment and recorded in OCI. For all other derivatives, all components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

Cash Flow Hedges

The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments.

In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were ($4) million and ($2) million for the three months and nine months ended September 30, 2026, respectively, and $14 million and $25 million for the three months and nine months ended September 30, 2025, respectively.

At September 30, 2026 and December 31, 2025, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed two years and three years, respectively.

At September 30, 2026 and December 31, 2025, the balance in AOCI associated with cash flow hedges was ($319) million and ($147) million, respectively.

All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

At September 30, 2026, the Company expected to reclassify $207 million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months.

NIFO Hedges

The Company uses foreign currency forwards to hedge portions of its NIFO against adverse movements in exchange rates. The Company assesses hedge effectiveness of its derivatives based upon the change in forward rates. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.

When NIFOs are sold or substantially liquidated, the amounts in AOCI are reclassified to the statements of operations.

50


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

Credit Derivatives

In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the interim condensed consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps.

The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at:

September 30, 2026December 31, 2025
Rating Agency Designation of Referenced
Credit Obligations (1)
Estimated
Fair Value
of Credit
Default
Swaps
Maximum
Amount of
Future
Payments under
Credit Default
Swaps
Weighted
Average
Years to
Maturity (2)
Estimated
Fair Value
of Credit
Default
Swaps
Maximum
Amount of
Future
Payments under
Credit Default
Swaps
Weighted
Average
Years to
Maturity (2)
(Dollars in millions)
Aaa/Aa/A
Credit default swaps referencing indices$21 $3,775 0.6$45 $3,777 1.4
Subtotal21 3,775 0.645 3,777 1.4
Baa
Single name credit default swaps (3)— 15 1.7— 15 2.5
Credit default swaps referencing indices107 8,871 5.149 2,714 4.9
Subtotal107 8,886 5.049 2,729 4.9
Ba
Credit default swaps referencing indices— 24 0.21 24 1.0
Subtotal— 24 0.21 24 1.0
B
Credit default swaps referencing indices16 230 3.96 74 3.0
Subtotal16 230 3.96 74 3.0
Caa
Credit default swaps referencing indices— 15 0.2(1)15 1.0
Subtotal— 15 0.2(1)15 1.0
Total$144 $12,930 3.7$100 $6,619 2.8

__________________

(1)The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service, Inc. (“Moody’s”), Standard & Poor’s Global Ratings (“S&P”) and Fitch Ratings, Inc. If no rating is available from a rating agency, then an internally developed rating is used.

(2)The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts.

(3)Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals.

Credit Risk on Freestanding Derivatives

The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements.

51


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s bilateral contracts between two counterparties (“OTC-bilateral”) derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law.

The Company’s over-the-counter derivatives are cleared and settled through central clearing counterparties (“OTC-cleared”) and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives.

See Note 10 for a description of the impact of credit risk on the valuation of derivatives.

The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at:

September 30, 2026December 31, 2025
Derivatives Subject to a Master Netting Arrangement or a Similar ArrangementAssetsLiabilitiesAssetsLiabilities
(In millions)

Gross estimated fair value of derivatives:

OTC-bilateral (1)

$5,134 $3,223 $5,406 $2,897 

OTC-cleared (1)

138 15 66 11 

Exchange-traded

— — 3 — 

Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1)

5,272 3,238 5,475 2,908 

Gross amounts not offset on the interim condensed consolidated balance sheets:

Gross estimated fair value of derivatives: (2)

OTC-bilateral

(2,198)(2,198)(2,006)(2,006)

OTC-cleared

(10)(10)(5)(5)

Cash collateral: (3), (4)

OTC-bilateral

(1,385)— (1,620)— 

OTC-cleared

(126)— (56)— 

Securities collateral: (5)

OTC-bilateral

(1,410)(1,021)(1,772)(890)

OTC-cleared

— (4)— (5)

Exchange-traded

— — — — 

Net amount after application of master netting agreements and collateral

$143 $5 $16 $2 

__________________

(1)At September 30, 2026 and December 31, 2025, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $106 million and $87 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of ($20) million and ($7) million, respectively.

(2)Gross estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals.

52


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

(3)Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet.

(4)The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2026 and December 31, 2025, the Company received excess cash collateral of $31 million and $4 million, respectively, and provided excess cash collateral of $9 million and $3 million, respectively, which are not included in the table above due to the foregoing limitation.

(5)Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2026, none of the collateral had been sold and $153 million was re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2026 and December 31, 2025, the Company received excess securities collateral with an estimated fair value of $226 million and $336 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2026 and December 31, 2025, the Company provided excess securities collateral with an estimated fair value of $760 million and $798 million, respectively, for its OTC-bilateral derivatives, $464 million and $465 million, respectively, for its OTC-cleared derivatives, and $32 million and $93 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.

The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. The Company’s netting agreements for derivatives generally contain provisions that require the counterparty (or its guarantor, if applicable) to maintain specified minimum credit ratings above investment grade level from Moody’s, S&P or both. In those agreements, if the credit rating of the counterparty (or its guarantor, if applicable) were to fall below the applicable minimum rating, that counterparty would be in violation of these provisions, and the Company could terminate the transactions and demand immediate settlement and payment based on reasonable valuation of the derivatives. A significant portion of the Company’s netting agreements for derivatives grant similar rights to the counterparty to terminate the transactions and demand immediate settlement and payment if the Company’s financial strength rating were to fall below specified minimum levels above investment grade.

The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged.

September 30, 2026December 31, 2025

Derivatives
Subject to
Financial

Strength-Contingent
Provisions

Derivatives
Not Subject
to Financial
Strength-Contingent
Provisions
Total

Derivatives
Subject to
Financial

Strength-Contingent
Provisions

Derivatives
Not Subject
to Financial
Strength-Contingent
Provisions
Total
(In millions)
Estimated fair value of derivatives in a net liability position$1,024 $— $1,024 $881 $10 $891 

Estimated fair value of collateral provided:

Fixed maturity securities AFS$1,404 $— $1,404 $1,279 $10 $1,289 

53


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

9. Derivatives (continued)

Embedded Derivatives

The Company issues or assumes certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives.

The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at:

Balance Sheet LocationSeptember 30, 2026December 31, 2025
(In millions)
Embedded derivatives within asset host contracts:
Assumed on affiliated reinsuranceOther invested assets$374 $22 
Funds withheld on affiliated assumed reinsuranceOther invested assets(102)31 
Total$272 $53 
Embedded derivatives within liability host contracts:
Assumed on affiliated reinsuranceOther liabilities$— $53 
Funds withheld on affiliated ceded reinsuranceOther liabilities(656)(281)
Fixed annuities with equity indexed returnsPABs546 67 
Funds withheld on unaffiliated ceded reinsuranceOther liabilities(294)(5)

Total

$(404)$(166)

54


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value

Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts.

Recurring Fair Value Measurements

The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at:

September 30, 2026
Fair Value Hierarchy
Level 1Level 2Level 3

Total 

Estimated

Fair Value

(In millions)

Assets

Fixed maturity securities AFS:

U.S. corporate

$— $41,882 $7,417 $49,299 

RMBS

— 26,558 687 27,245 
U.S. government and agency10,127 11,000 — 21,127 
Foreign corporate— 16,601 9,505 26,106 
ABS & CLO— 17,240 989 18,229 

Municipals

— 4,823 83 4,906 

CMBS

— 4,931 123 5,054 

Foreign government

— 3,610 16 3,626 

Total fixed maturity securities AFS

10,127 126,645 18,820 155,592 

Short-term investments

2,043 498 10 2,551 

Other investments

11 802 1,726 2,539 

Derivative assets: (1)

Interest rate

— 2,327 — 2,327 

Foreign currency exchange rate

— 2,068 — 2,068 

Credit

— 146 — 146 

Equity market

— 625 — 625 

Total derivative assets

— 5,166 — 5,166 

Embedded derivatives within asset host contracts (2)

— — 272 272 

MRBs

— — 314 314 

Reinsured MRBs (3)

— — 63 63 

Separate account assets (4)

11,195 57,408 779 69,382 

Total assets (5)

$23,376 $190,519 $21,984 $235,879 

Liabilities

Derivative liabilities: (1)

Interest rate

$— $2,053 $— $2,053 

Foreign currency exchange rate

— 821 — 821 

Credit

— 5 — 5 

Equity market

— 366 13 379 

Total derivative liabilities

— 3,245 13 3,258 

Embedded derivatives within liability host contracts (2)

— — (404)(404)

Notes issued by CFEs

— — 803 803 

MRBs

— — 1,721 1,721 

Total liabilities

$— $3,245 $2,133 $5,378 

55


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

December 31, 2025
Fair Value Hierarchy
Level 1Level 2Level 3

Total

Estimated

Fair Value

(In millions)

Assets

Fixed maturity securities AFS:

U.S. corporate

$— $43,351 $7,251 $50,602 

RMBS

— 26,031 1,208 27,239 
U.S. government and agency14,337 12,364 — 26,701 
Foreign corporate— 17,148 9,323 26,471 
ABS & CLO— 13,822 729 14,551 

Municipals

— 5,588 1 5,589 

CMBS

— 4,998 115 5,113 

Foreign government

— 3,051 15 3,066 

Total fixed maturity securities AFS

14,337 126,353 18,642 159,332 

Short-term investments

1,763 424 34 2,221 

Other investments

13 12 1,459 1,484 

Derivative assets: (1)

Interest rate

— 2,501 — 2,501 

Foreign currency exchange rate

— 2,554 — 2,554 

Credit

— 103 — 103 

Equity market

3 227 — 230 

Total derivative assets

3 5,385 — 5,388 

Embedded derivatives within asset host contracts (2)

— — 53 53 

MRBs

— — 257 257 

Reinsured MRBs (3)

— — 285 285 

Separate account assets (4)

11,694 60,951 866 73,511 

Total assets (5)

$27,810 $193,125 $21,596 $242,531 

Liabilities

Derivative liabilities: (1)

Interest rate

$— $1,615 $— $1,615 

Foreign currency exchange rate

— 1,028 — 1,028 

Credit

— 6 — 6 

Equity market

— 265 1 266 

Total derivative liabilities

— 2,914 1 2,915 

Embedded derivatives within liability host contracts (2)

— — (166)(166)

Notes issued by CFEs

— — — — 

MRBs

— — 2,201 2,201 

Total liabilities

$— $2,914 $2,036 $4,950 

__________________

(1)Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables.

(2)Embedded derivatives within asset host contracts are presented within other invested assets on the interim condensed consolidated balance sheets. Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the interim condensed consolidated balance sheets.

56


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

(3)Reinsured MRBs are presented within premiums, reinsurance and other receivables on the interim condensed consolidated balance sheets.

(4)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities.

(5)Total assets included in the fair value hierarchy exclude OLPI that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. The estimated fair value of such investments was $31 million and $38 million at September 30, 2026 and December 31, 2025, respectively.

The following describes the valuation methodologies used to measure assets and liabilities at fair value.

Investments

Securities, Short-term Investments and Other Investments

When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings, and valuation of these securities does not involve management’s judgment.

When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based, in large part, on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments.

The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein.

The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g., cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs.

57


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

Instrument

Level 2

Observable Inputs

Level 3

Unobservable Inputs

Fixed maturity securities AFS

U.S. corporate and Foreign corporate securities

Valuation Approaches: Principally the market and income approaches.

Valuation Approaches: Principally the market approach.

Key Inputs:

Key Inputs:

•

quoted prices in markets that are not active

•

illiquidity premium

•benchmark yields; spreads off benchmark yields; new issuances; issuer ratings•delta spread adjustments to reflect specific credit-related issues
•trades of identical or comparable securities; duration•credit spreads
•

privately-placed securities are valued using the additional key inputs:

•

quoted prices in markets that are not active for identical or similar

securities that are less liquid and based on lower levels of trading

activity than securities classified in Level 2

•

market yield curve; call provisions

•

observable prices and spreads for similar public or private securities that

incorporate the credit quality and industry sector of the issuer

•

independent non-binding broker quotations
•

delta spread adjustments to reflect specific credit-related issues

U.S. government and agency securities, Municipals and Foreign government securities

Valuation Approaches: Principally the market approach.

Valuation Approaches: Principally the market approach.

Key Inputs:

Key Inputs:

•

quoted prices in markets that are not active

•

independent non-binding broker quotations

•

benchmark U.S. Treasury yield or other yields

•

quoted prices in markets that are not active for identical or similar

securities that are less liquid and based on lower levels of trading

activity than securities classified in Level 2

•

the spread off the U.S. Treasury yield curve for the identical security

•issuer ratings and issuer spreads; broker-dealer quotations•credit spreads
•

comparable securities that are actively traded

Structured Products

Valuation Approaches: Principally the market and income approaches.

Valuation Approaches: Principally the market and income approaches.

Key Inputs:

Key Inputs:

•quoted prices in markets that are not active•

credit spreads

•

spreads for actively traded securities; spreads off benchmark yields

•

quoted prices in markets that are not active for identical or similar

securities that are less liquid and based on lower levels of trading

activity than securities classified in Level 2

•

expected prepayment speeds and volumes

•

current and forecasted loss severity; ratings; geographic region

•

independent non-binding broker quotations

•

weighted average coupon and weighted average maturity

•credit ratings
•average delinquency rates; DSCR
•

credit ratings

•

issuance-specific information, including, but not limited to:

•collateral type; structure of the security; vintage of the loans
•payment terms of the underlying assets
•

payment priority within the tranche; deal performance

58


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

Instrument

Level 2

Observable Inputs

Level 3

Unobservable Inputs

Short-term investments and Other investments

•Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above; while certain other investments are similar to equity securities. The valuation approaches and observable inputs used in their valuation are also similar to those described above. Other investments contain equity securities valued using quoted prices in markets that are not considered active. •

Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above, while certain other investments are similar to equity securities. The valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments contain equity securities that use key unobservable inputs such as credit ratings, issuance structures and those described above for fixed maturities AFS. Other investments also include certain REJVs and use the valuation approach and key inputs as described for OLPI below.

Separate account assets and Separate account liabilities (1)

Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly

Key Input:•N/A
•

quoted prices or reported NAV provided by the fund managers

OLPI

•N/A

Valued giving consideration to the underlying holdings of the partnerships and adjusting, if appropriate.

Key Input:

•

NAV

__________________

(1)Estimated fair value equals carrying value, based on the value of the underlying assets, including mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, OLPI, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.”

Derivatives

The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models.

The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. With respect to certain OTC-bilateral and OTC-cleared derivatives, management may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives.

Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income.

59


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

The credit risk of both the counterparty and the Company is considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by the counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period.

Freestanding Derivatives

Level 2 Valuation Approaches and Key Inputs:

This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3.

Level 3 Valuation Approaches and Key Inputs:

These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data.

Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows:

InstrumentInterest RateForeign Currency
Exchange Rate
CreditEquity Market

Inputs common to Level 2 and Level 3 by instrument type

•

swap yield curves

•

swap yield curves

•

swap yield curves

•

swap yield curves

•

basis curves

•

basis curves

•

credit curves

•

spot equity index levels

•interest rate volatility (1)•

currency spot rates

•

recovery rates

•

dividend yield curves

•cross currency basis curves•

equity volatility (1)

Level 3•

N/A

•

N/A

•

N/A

•

dividend yield curves (2)

•

equity volatility (1), (2)

•correlation between model inputs (1)

__________________

(1)Option-based only.

(2)Extrapolation beyond the observable limits of the curve(s).

Embedded Derivatives

Embedded derivatives principally include equity-indexed annuity contracts and investment risk related to certain affiliated and unaffiliated reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income.

60


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

The estimated fair value of the embedded derivatives within funds withheld related to certain assumed affiliated reinsurance and certain ceded affiliated and unaffiliated reinsurance, as well as experience refund provisions related to certain assumed affiliated reinsurance, is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the related reinsurance liabilities. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of these embedded derivatives is included, along with their underlying host contracts, in other liabilities and other invested assets on the interim condensed consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income.

The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk.

Notes Issued by CFEs

The estimated fair value of these notes is based on the estimated fair value of the corresponding securities which collateralize the notes. Since the notes are valued based on referenced collateral, they are classified as Level 3.

MRBs

See Note 5 for information on the Company’s valuation approaches and key inputs for MRBs.

Transfers between Levels

Overall, transfers between levels occur when there are changes in the observability of inputs and market activity.

Transfers into or out of Level 3:

Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.

61


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at:

September 30, 2026December 31, 2025Impact of
Increase in Input
on Estimated
Fair Value (2)

Valuation

Techniques

Significant
Unobservable Inputs
RangeWeighted
Average (1)
RangeWeighted
Average (1)

Fixed maturity securities AFS (3)

U.S. corporate and foreign corporate

•

Matrix pricing

•Offered quotes (4)—-1159232-12796Increase

•

Market pricing

•

Quoted prices (4)

—-10096—-10089Increase

RMBS

•

Market pricing

•

Quoted prices (4)

30-1109333-11496Increase (5)
ABS & CLO

•

Market pricing

•

Quoted prices (4)

—-20410023-142100Increase (5)
MRBs and Reinsured MRBs
Direct, assumed and ceded guaranteed minimum benefits•Option pricing techniques

•

Mortality rates:

Ages 0 - 400.01%-0.12%0.05%0.01%-0.13%0.05%

(6)

Ages 41 - 60

0.06%-0.65%0.23%0.05%-0.68%0.22%

(6)

Ages 61 - 115

0.37%-100%1.43%0.35%-100%1.23%

(6)

•

Lapse rates:

Durations 1 - 10

0.80%-20.10%13.88%0.80%-20.10%13.37%

Decrease (7)

Durations 11 - 20

3.30%-10.55%7.87%3.30%-10.55%8.17%

Decrease (7)

Durations 21 - 116

1.20%-10.55%8.07%1.20%-10.55%7.48%

Decrease (7)

•

Utilization rates

0.20%-13.78%0.52%0.20%-16.25%0.54%

Increase (8)

•

Withdrawal rates

0%-7.75%5.04%0%-7.75%4.92%(9)

•

Long-term equity volatilities

16.97%-22.56%19.10%16.87%-22.49%18.96%

Increase (10)

•

Nonperformance risk spread

0.35%-0.73%0.65%0.33%-0.65%0.58%

Decrease (11)

__________________

(1)The weighted average for fixed maturity securities AFS is determined based on the estimated fair value of the securities. The weighted average for MRBs is determined based on a combination of account values and experience data.

(2)The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions.

(3)Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations.

(4)Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par.

(5)Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates.

(6)Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on Company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates results in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates results in a decrease (increase) in the estimated fair value of MRBs.

62


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

(7)Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(8)The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(9)The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value.

(10)Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs.

(11)Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs.

All other classes of securities classified within Level 3, including those within Other investments, Separate account assets, Notes issued by CFEs, and Embedded derivatives within funds withheld related to certain assumed affiliated reinsurance and certain ceded affiliated and unaffiliated reinsurance, use the same valuation techniques and significant unobservable inputs as previously described for Level 3 securities. Generally, all other classes of assets and liabilities classified within Level 3 that are not included above use the same valuation techniques and significant unobservable inputs as previously described for Level 3. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table. The valuation techniques and significant unobservable inputs used in the fair value measurement for the more significant assets measured at estimated fair value on a nonrecurring basis and determined using significant unobservable inputs (Level 3) are summarized in “— Nonrecurring Fair Value Measurements.”

63


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

The following tables summarize the change of all assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3), excluding MRBs (see Note 5):

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Fixed Maturity Securities AFS
Corporate (6)Structured
Products
MunicipalsForeign
Government
Short-term
Investments
(In millions)
Three Months Ended September 30, 2026
Balance, beginning of period$17,577 $2,089 $— $15 $43 

Total realized/unrealized gains (losses) included in net income (loss) (1), (2)

— 1 — 1 (1)

Total realized/unrealized gains (losses) included in AOCI

(708)(4)— (1)1 

Purchases (3)

918 748 83 1 9 

Sales (3)

(847)(85)— (1)(42)

Issuances (3)

— — — — — 

Settlements (3)

— — — — — 

Transfers into Level 3 (4)

3 96 — 1 — 

Transfers out of Level 3 (4)

(21)(1,046)— — — 
Balance, end of period$16,922 $1,799 $83 $16 $10 
Three Months Ended September 30, 2025
Balance, beginning of period$15,763 $2,259 $— $15 $3 

Total realized/unrealized gains (losses) included in net income (loss) (1), (2)

(37)1 — — — 

Total realized/unrealized gains (losses) included in AOCI

85 19 — — — 

Purchases (3)

678 914 — 2 13 

Sales (3)

(699)(428)— — (1)

Issuances (3)

— — — — — 

Settlements (3)

— — — — — 

Transfers into Level 3 (4)

325 23 — — — 

Transfers out of Level 3 (4)

(68)(264)— — — 
Balance, end of period$16,047 $2,524 $— $17 $15 

Changes in unrealized gains (losses) included in net income (loss) for the instruments still held

at September 30, 2026 (5)

$(1)$2 $— $— $— 

Changes in unrealized gains (losses) included in net income (loss) for the instruments still held

at September 30, 2025 (5)

$(37)$2 $— $— $— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2026 (5)

$(725)$(5)$— $(1)$— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2025 (5)

$90 $17 $— $(1)$— 

64


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

Other

Investments

Net
Derivatives (7)
Net Embedded
Derivatives (8)
Separate
Accounts (9) 
Notes Issued by CFEs

(In millions)

Three Months Ended September 30, 2026
Balance, beginning of period$1,683 $(9)$49 $769 $(791)

Total realized/unrealized gains (losses) included in net income (loss) (1), (2)

17 (4)776 (4)14 

Total realized/unrealized gains (losses) included in AOCI

— — — — — 

Purchases (3)

97 — — 35 — 

Sales (3)

(38)— — (20)— 

Issuances (3)

— — (163)— (26)

Settlements (3)

— — 14 — — 

Transfers into Level 3 (4)

4 — — — — 

Transfers out of Level 3 (4)

(37)— — (1)— 
Balance, end of period$1,726 $(13)$676 $779 $(803)
Three Months Ended September 30, 2025
Balance, beginning of period$1,439 $— $385 $888 $— 

Total realized/unrealized gains (losses) included in net income (loss) (1), (2)

48 — (159)4 — 

Total realized/unrealized gains (losses) included in AOCI

— — — — — 

Purchases (3)

4 — — 35 — 

Sales (3)

(7)— — (48)— 

Issuances (3)

— — — — — 

Settlements (3)

— — — — — 

Transfers into Level 3 (4)

— — — 3 — 

Transfers out of Level 3 (4)

— — — (23)— 
Balance, end of period$1,484 $— $226 $859 $— 

Changes in unrealized gains (losses) included in net income (loss) for the instruments still held

at September 30, 2026 (5)

$11 $(4)$777 $— $14 

Changes in unrealized gains (losses) included in net income (loss) for the instruments still held

at September 30, 2025 (5)

$65 $— $(159)$— $— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2026 (5)

$— $— $— $— $— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2025 (5)

$— $— $— $— $— 

65


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
Fixed Maturity Securities AFS
Corporate (6)Structured
Products

Municipals

Foreign
Government
Short-term
Investments
(In millions)
Nine Months Ended September 30, 2026

Balance, beginning of period

$16,574 $2,052 $1 $15 $34 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)(9)(5)— — — 
Total realized/unrealized gains (losses) included in AOCI(898)(16)— — (4)

Purchases (3)

3,347 879 83 4 11 

Sales (3)

(1,976)(232)— (3)(21)

Issuances (3)

— — — — — 

Settlements (3)

— — — — — 

Transfers into Level 3 (4)

63 131 — — — 

Transfers out of Level 3 (4)

(179)(1,010)(1)— (10)

Balance, end of period

$16,922 $1,799 $83 $16 $10 
Nine Months Ended September 30, 2025

Balance, beginning of period

$15,091 $5,590 $7 $12 $1 

Total realized/unrealized gains (losses) included in net income (loss) (1), (2)

(73)11 1 1 — 
Total realized/unrealized gains (losses) included in AOCI828 36 (1)4 (1)

Purchases (3)

1,614 1,319 — 2 16 

Sales (3)

(1,349)(922)(7)(1)(1)

Issuances (3)

— — — — — 

Settlements (3)

— — — — — 

Transfers into Level 3 (4)

220 29 — — — 

Transfers out of Level 3 (4)

(284)(3,539)— (1)— 

Balance, end of period

$16,047 $2,524 $— $17 $15 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2026 (5)$5 $(6)$— $— $— 
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2025 (5)$(62)$13 $— $— $— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2026 (5)

$(916)$(10)$— $(1)$— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2025 (5)

$796 $30 $— $3 $— 

66


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

Other

 Investments

Net
Derivatives (7)
Net Embedded
Derivatives (8)

Separate

Accounts (9) 

Notes Issued by CFEs

(In millions)

Nine Months Ended September 30, 2026

Balance, beginning of period

$1,459 $(1)$219 $866 $— 
Total realized/unrealized gains (losses) included in net income (loss) (1), (2)110 (12)832 (14)12 

Total realized/unrealized gains (losses) included in 

AOCI

— — — — — 

Purchases (3)

171 — — 48 (801)

Sales (3)

(30)— — (93)— 

Issuances (3)

— — (396)— (26)

Settlements (3)

— — 21 — 12 

Transfers into Level 3 (4)

16 — — — — 

Transfers out of Level 3 (4)

— — — (28)— 

Balance, end of period

$1,726 $(13)$676 $779 $(803)
Nine Months Ended September 30, 2025

Balance, beginning of period

$1,371 $3 $457 $859 $— 

Total realized/unrealized gains (losses) included in net income (loss) (1), (2)

122 (3)(387)(11)— 

Total realized/unrealized gains (losses) included in 

AOCI

— — — — — 

Purchases (3)

25 — — 62 — 

Sales (3)

(56)— — (45)— 

Issuances (3)

— — — — — 

Settlements (3)

— — 156 — — 

Transfers into Level 3 (4)

22 — — 4 — 

Transfers out of Level 3 (4)

— — — (10)— 

Balance, end of period

$1,484 $— $226 $859 $— 

Changes in unrealized gains (losses) included in net income (loss) for the instruments still held

at September 30, 2026 (5)

$84 $(12)$832 $— $12 

Changes in unrealized gains (losses) included in net income (loss) for the instruments still held

at September 30, 2025 (5)

$110 $— $(386)$— $— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2026 (5)

$— $— $— $— $— 

Changes in unrealized gains (losses) included in AOCI for the instruments still held

at September 30, 2025 (5)

$— $— $— $— $— 

__________________

(1)Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses). Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(2)Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward.

(3)Items purchased/issued and then sold/settled in the same period are excluded from the rollforward.

(4)Items transferred into and then out of Level 3 in the same period are excluded from the rollforward.

67


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

(5)Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).

(6)Comprised of U.S. and foreign corporate securities.

(7)Freestanding derivative assets and liabilities are presented net for purposes of the rollforward.

(8)Embedded derivative assets and liabilities are presented net for purposes of the rollforward.

(9)Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss).

Fair Value Option

The Company has elected the FVO for certain invested assets held by, and notes issued by, CFEs.

The unpaid principal balance on the invested assets held by CFEs exceeded the estimated fair value by $29 million at September 30, 2026.

The estimated fair value on the notes issued by CFEs exceeded the unpaid principal balance by $21 million at September 30, 2026.

Nonrecurring Fair Value Measurements

The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment), using significant unobservable inputs (Level 3).

September 30, 2026December 31, 2025

(In millions)

Carrying value after measurement:

Mortgage loans (1)

$1,137 $730 

Real estate and REJVs (2)

$166 $— 
Three Months
Ended
September 30,
Nine Months
Ended
September 30,
2026202520262025

(In millions)

Net investment gains (losses):

Mortgage loans (1)

$(98)$(37)$(321)$(351)

Real estate and REJVs (2)

$(20)$— $(186)$— 

__________________

(1)Estimated fair values of impaired mortgage loans are based on the underlying collateral or discounted cash flows. See Note 8.

(2)Estimated fair values of impaired real estate and REJVs are based on appraised values.

Fair Value of Financial Instruments Carried at Other Than Fair Value

The following tables provide fair value information for financial instruments that are carried on the balance sheet at amounts other than fair value. The following tables exclude cash and cash equivalents, which are primarily classified as Level 1, and accrued investment income and payables for collateral under securities loaned and other transactions, which are primarily classified as Level 2. The Company believes that due to the short-term nature of these excluded financial instruments, the estimated fair value approximates carrying value.

68


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

10. Fair Value (continued)

The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at:

September 30, 2026
Fair Value Hierarchy
Carrying
Value
Level 1Level 2Level 3Total
Estimated
Fair Value
(In millions)

Assets

Mortgage loans

$55,140 $— $— $52,117 $52,117 

Policy loans

$5,308 $— $— $5,461 $5,461 

Other invested assets

$2,057 $— $1,754 $251 $2,005 

Premiums, reinsurance and other receivables

$14,068 $— $828 $13,336 $14,164 

Liabilities

PABs

$91,553 $— $— $88,470 $88,470 

Long-term debt

$994 $— $1,053 $— $1,053 

Other liabilities

$13,114 $— $1,754 $11,135 $12,889 

Separate account liabilities

$19,824 $— $19,824 $— $19,824 
December 31, 2025
Fair Value Hierarchy
Carrying
Value
Level 1Level 2Level 3Total
Estimated
Fair Value
(In millions)

Assets

Mortgage loans

$55,870 $— $— $54,507 $54,507 

Policy loans

$5,596 $— $— $5,879 $5,879 

Other invested assets

$1,808 $— $1,792 $— $1,792 
Premiums, reinsurance and other receivables$13,925 $— $354 $13,304 $13,658 

Liabilities

PABs

$88,074 $— $— $87,444 $87,444 

Long-term debt

$1,043 $— $1,146 $— $1,146 

Other liabilities

$12,004 $— $335 $11,083 $11,418 

Separate account liabilities

$21,835 $— $21,835 $— $21,835 

69


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Equity

AOCI

Information regarding changes in the balances of each component of AOCI attributable to Metropolitan Life Insurance Company was as follows:

Three Months 
 Ended 
 September 30, 2026

Unrealized

Investment Gains

(Losses), Net of

Related Offsets (1)

Deferred
Gains (Losses)
on Derivatives

FPBs Discount Rate Remeasurement Gains (Losses)

MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses)

Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)
Balance, beginning of period$(6,368)$74 $728 $(37)$(88)$(145)$(5,836)
OCI before reclassifications(7,248)(586)4,965 (37)9 — (2,897)
Deferred income tax benefit (expense)1,575 123 (1,121)8 (1)— 584 
AOCI before reclassifications, net of income tax(12,041)(389)4,572 (66)(80)(145)(8,149)
Amounts reclassified from AOCI171 91 — — — 3 265 
Deferred income tax benefit (expense)(37)(19)— — — (1)(57)
Amounts reclassified from AOCI, net of income tax134 72 — — — 2 208 
Balance, end of period$(11,907)$(317)$4,572 $(66)$(80)$(143)$(7,941)
Three Months 
 Ended 
 September 30, 2025

Unrealized

Investment Gains

(Losses), Net of

Related Offsets (1)

Deferred
Gains (Losses)
on Derivatives

FPBs Discount Rate Remeasurement Gains (Losses)

MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses)

Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)
Balance, beginning of period$(5,752)$(153)$134 $(28)$(134)$(131)$(6,064)
OCI before reclassifications1,054 115 (249)(10)66 — 976 
Deferred income tax benefit (expense)(313)(24)261 2 (13)— (87)
AOCI before reclassifications, net of income tax(5,011)(62)146 (36)(81)(131)(5,175)
Amounts reclassified from AOCI95 108 — — — 2 205 
Deferred income tax benefit (expense)(20)(23)— — — — (43)
Amounts reclassified from AOCI, net of income tax75 85 — — — 2 162 
Balance, end of period$(4,936)$23 $146 $(36)$(81)$(129)$(5,013)
Nine Months
Ended
September 30, 2026
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
Deferred
Gains (Losses)
on Derivatives

FPBs Discount Rate Remeasurement Gains (Losses)

MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses)

Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)

Balance, beginning of period

$(5,226)$(116)$383 $(51)$(76)$(150)$(5,236)
OCI before reclassifications(8,982)(611)5,465 (20)(7)1 (4,154)
Deferred income tax benefit (expense)1,980 128 (1,276)5 3 — 840 
AOCI before reclassifications, net of income tax(12,228)(599)4,572 (66)(80)(149)(8,550)
Amounts reclassified from AOCI408 357 — — — 8 773 
Deferred income tax benefit (expense)(87)(75)— — — (2)(164)
Amounts reclassified from AOCI, net of income tax321 282 — — — 6 609 
Balance, end of period$(11,907)$(317)$4,572 $(66)$(80)$(143)$(7,941)

70


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Equity (continued)

Nine Months
Ended
September 30, 2025
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
Deferred
Gains (Losses)
on Derivatives

FPBs Discount Rate Remeasurement Gains (Losses)

MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses)

Foreign
Currency
Translation
Adjustments
Defined
Benefit
Plans
Adjustment
Total
(In millions)

Balance at December 31, 2024

$(8,651)$959 $1,972 $(30)$(111)$(133)$(5,994)
Cumulative effects of change in accounting principles for equity method investee at January 1, 202570 — (1,144)— — — (1,074)
OCI before reclassifications4,387 162 (1,044)(7)36 (1)3,533 
Deferred income tax benefit (expense)(1,002)(34)362 1 (6)— (679)
AOCI before reclassifications, net of income tax(5,196)1,087 146 (36)(81)(134)(4,214)
Amounts reclassified from AOCI329 (1,347)— — — 6 (1,012)
Deferred income tax benefit (expense)(69)283 — — — (1)213 
Amounts reclassified from AOCI, net of income tax260 (1,064)— — — 5 (799)
Balance, end of period$(4,936)$23 $146 $(36)$(81)$(129)$(5,013)

__________________

(1)Primarily unrealized gains (losses) on fixed maturity securities.

71


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

11. Equity (continued)

Information regarding amounts reclassified out of each component of AOCI was as follows:

Three Months
Ended
September 30,
Nine Months
Ended
September 30,
2026202520262025
AOCI ComponentsAmounts Reclassified from AOCIConsolidated Statements of
Operations and
Comprehensive Income (Loss)
Locations
(In millions)

Unrealized investment gains (losses):

Unrealized investment gains (losses)

$(147)$(90)$(391)$(317)Net investment gains (losses)

Unrealized investment gains (losses)

— (1)— (2)Net investment income

Unrealized investment gains (losses)

(24)(4)(17)(10)Net derivative gains (losses)

Unrealized investment gains (losses), before income tax

(171)(95)(408)(329)

Income tax (expense) benefit

37 20 87 69 

Unrealized investment gains (losses), net of income tax

(134)(75)(321)(260)
Deferred gains (losses) on derivatives - cash flow hedges:

Interest rate derivatives

— 4 2 30 Net investment income

Interest rate derivatives

1 (26)(9)(17)Net investment gains (losses)

Foreign currency exchange rate derivatives

— 1 2 3 Net investment income

Foreign currency exchange rate derivatives

(92)(87)(352)1,331 Net investment gains (losses)

Gains (losses) on cash flow hedges, before income tax

(91)(108)(357)1,347 

Income tax (expense) benefit

19 23 75 (283)

Gains (losses) on cash flow hedges, net of income tax

(72)(85)(282)1,064 

Defined benefit plans adjustment: (1)

Amortization of net actuarial gains (losses)

(3)(2)(9)(7)

Amortization of prior service (costs) credit

— — 1 1 

Amortization of defined benefit plan items, before income tax

(3)(2)(8)(6)

Income tax (expense) benefit

1 — 2 1 

Amortization of defined benefit plan items, net of income tax

(2)(2)(6)(5)

Total reclassifications, net of income tax

$(208)$(162)$(609)$799 

__________________

(1)These AOCI components are included in the computation of net periodic benefit costs.

72


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

12. Other Revenues and Other Expenses

Other Revenues

Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows:

Three Months
Ended
September 30,
Nine Months
Ended
September 30,
2026202520262025
(In millions)
Prepaid legal plans$107 $109 $343 $329 
Administrative services-only contracts 80 71 241 216 
Recordkeeping and administrative services (1)34 35 101 104 

Other revenue related to service contracts from customers

10 17 26 43 

Total revenues related to service contracts from customers

231 232 711 692 
Other (2)198 195 600 591 

Total other revenues

$429 $427 $1,311 $1,283 

__________________

(1)Related to products and businesses no longer actively marketed by the Company.

(2)Primarily includes reinsurance ceded. See Note 15.

Other Expenses

Information on other expenses was as follows:

Three Months 
 Ended 
 September 30,
Nine Months
Ended
September 30,
2026202520262025
(In millions)

Amortization of DAC and VOBA

$65 $66 $191 $200 

Interest expense on debt

27 27 75 83 

General and administrative expenses (1)

687 628 2,056 1,906 

Commissions and other variable expenses

663 510 2,044 1,440 

Capitalization of DAC

(64)(31)(169)(79)

Premium taxes, other taxes, and licenses & fees

107 97 310 276 

Pension, postretirement and postemployment benefit costs

57 63 170 187 

Total other expenses (2)

$1,542 $1,360 $4,677 $4,013 

__________________

(1)Includes ($13) million and ($74) million for the three months and nine months ended September 30, 2026, respectively, and ($42) million and ($110) million for the three months and nine months ended September 30, 2025, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.

(2)See Note 15 for a discussion of affiliated expenses.

73


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

13. Income Tax

For the three months and nine months ended September 30, 2026, the effective tax rate on income (loss) before provision for income tax was 19% and 18%, respectively. The Company’s effective tax rate for both the three months and nine months ended September 30, 2026 differed from the U.S. statutory rate of 21% primarily due to tax benefits from (i) non-taxable investment income; and (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments.

For the three months and nine months ended September 30, 2025, the effective tax rate on income (loss) before provision for income tax was 14% and 13%, respectively. The Company’s effective tax rate for the three months ended September 30, 2025 differed from the U.S. statutory rate of 21% primarily due to tax benefits from (i) non-taxable investment income; and (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments. The Company’s effective tax rate for the nine months ended September 30, 2025 differed from the U.S. statutory rate of 21% primarily due to tax benefits from (i) non-taxable investment income; (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments; and (iii) the corporate tax deduction for stock-based compensation.

14. Contingencies, Commitments and Guarantees

Contingencies

Litigation

The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s interim condensed consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lender, employer, investor, investment advisor, broker-dealer, and taxpayer.

The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the U.S. where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries.

It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. In certain circumstances where liabilities have been established there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at September 30, 2026. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods.

Matters as to Which an Estimate Can Be Made

For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of September 30, 2026, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million.

74


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

14. Contingencies, Commitments and Guarantees (continued)

Matters as to Which an Estimate Cannot Be Made

For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews.

Asbestos-Related Claims

Metropolitan Life Insurance Company is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. Metropolitan Life Insurance Company has never engaged in the business of manufacturing or selling asbestos-containing products, nor has Metropolitan Life Insurance Company issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of Metropolitan Life Insurance Company’s employees during the period from the 1920s through approximately the 1950s and allege that Metropolitan Life Insurance Company learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. Metropolitan Life Insurance Company believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against Metropolitan Life Insurance Company.

Metropolitan Life Insurance Company’s defenses include that: (i) Metropolitan Life Insurance Company owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of Metropolitan Life Insurance Company; (iii) Metropolitan Life Insurance Company’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against Metropolitan Life Insurance Company, while other trial courts have denied Metropolitan Life Insurance Company’s motions. There can be no assurance that Metropolitan Life Insurance Company will receive favorable decisions on motions in the future. While most cases brought to date have settled, Metropolitan Life Insurance Company intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials.

As reported in the 2025 Annual Report, Metropolitan Life Insurance Company received approximately 2,782 asbestos-related claims in 2025. For the nine months ended September 30, 2026 and 2025, Metropolitan Life Insurance Company received approximately 2,047 and 2,013 new asbestos-related claims, respectively. See Note 19 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for historical information concerning asbestos claims and Metropolitan Life Insurance Company’s update to its recorded liability at December 31, 2025. The number of asbestos cases that may be brought, the aggregate amount of any liability that Metropolitan Life Insurance Company may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year.

The ability of Metropolitan Life Insurance Company to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against Metropolitan Life Insurance Company when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts.

The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position.

75


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

14. Contingencies, Commitments and Guarantees (continued)

The Company believes adequate provision has been made in its interim condensed consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. Metropolitan Life Insurance Company’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis.

Metropolitan Life Insurance Company reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the U.S., assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, Metropolitan Life Insurance Company has updated its liability analysis for asbestos-related claims through September 30, 2026.

Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017)

Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the State of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., Metropolitan Life Insurance Company and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. In December 2020, the Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and Metropolitan Life Insurance Company’s motion to dismiss and remanded the case. The Relator filed a Fourth Amended Complaint in January 2023. On October 13, 2024, the trial court denied the defendants’ motion to dismiss the complaint. The Company intends to defend the action vigorously.

Commitments

Mortgage Loan Commitments

The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $1.8 billion and $2.0 billion at September 30, 2026 and December 31, 2025, respectively.

Commitments to Fund Partnership Investments, Bank Credit Facilities and Private Corporate Bond Investments

The Company commits to fund partnership investments and to lend funds under bank credit facilities and private corporate bond investments. The amounts of these unfunded commitments were $5.4 billion and $4.5 billion at September 30, 2026 and December 31, 2025, respectively.

Guarantees

In the normal course of its business, the Company has provided certain indemnities and guarantees to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $542 million, with a cumulative maximum of $642 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities or guarantees.

76


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

14. Contingencies, Commitments and Guarantees (continued)

In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future.

The Company’s recorded liabilities were $2 million at both September 30, 2026 and December 31, 2025 for indemnities and guarantees.

15. Related Party Transactions

The Company has entered into various service agreements with affiliates for services necessary to conduct its activities. Typical services provided under these agreements include personnel, policy administrative functions and distribution services. The bases for such charges are modified and adjusted by management when necessary or appropriate to reflect fairly and equitably the actual cost incurred by the Company and/or its affiliates. Expenses and fees incurred with affiliates related to these agreements, recorded in other expenses, were $806 million and $2.4 billion for the three months and nine months ended September 30, 2026, respectively, and $736 million and $2.3 billion for the three months and nine months ended September 30, 2025, respectively. Total revenues received from affiliates related to these agreements were $25 million and $65 million for the three months and nine months ended September 30, 2026, respectively, and $18 million and $55 million for the three months and nine months ended September 30, 2025, respectively. The Company had net payables to affiliates, related to the items discussed above, of $72 million at both September 30, 2026 and December 31, 2025.

The Company has issued group annuity and stable value contracts to MetLife Group, Inc. (“MLG”), an affiliate, and Company-owned life insurance policies (“COLI”) to a trust held by MLG, for the benefit of pension and other postretirement benefit plans, and active benefit plans, that are sponsored by MLG. These contracts and COLI are reported as separate account assets and liabilities. In addition, the Company has issued a group life insurance contract and group annuity contracts to MLG for pension and postretirement benefit plans sponsored by MLG, which are reported as PABs.

See Note 8 for additional information on related party transactions.

77


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

15. Related Party Transactions (continued)

Related Party Reinsurance Transactions

The Company has reinsurance agreements with certain of MetLife, Inc.’s subsidiaries, including MetLife Reinsurance Company of Charleston (“MRC”), MetLife Reinsurance Company of Vermont, MTL, Superior Vision Insurance, Inc. and MetLife Insurance K.K., all of which are related parties.

Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated statements of operations and comprehensive income (loss) was as follows:

Three Months
Ended
September 30,
Nine Months
Ended
September 30,
2026202520262025
(In millions)

Premiums

Reinsurance assumed

$1 $2 $5 $5 

Reinsurance ceded

(105)(103)(328)(321)

Net premiums

$(104)$(101)$(323)$(316)

Universal life and investment-type product policy fees

Reinsurance assumed

$16 $8 $41 $23 

Reinsurance ceded

1 — 2 (1)

Net universal life and investment-type product policy fees

$17 $8 $43 $22 

Other revenues

Reinsurance assumed

$27 $28 $79 $83 

Reinsurance ceded

114 112 338 338 

Net other revenues

$141 $140 $417 $421 

Policyholder benefits and claims

Reinsurance assumed

$1 $10 $14 $28 

Reinsurance ceded

(89)(82)(269)(257)

Net policyholder benefits and claims

$(88)$(72)$(255)$(229)
Policyholder liability remeasurement (gains) losses
Reinsurance assumed$3 $6 $5 $3 
Reinsurance ceded(3)6 (6)6 
Net policyholder liability remeasurement (gains) losses$— $12 $(1)$9 

Interest credited to PABs

Reinsurance assumed

$80 $89 $243 $259 

Reinsurance ceded

(2)(2)(7)(7)

Net interest credited to PABs

$78 $87 $236 $252 

Other expenses

Reinsurance assumed

$48 $11 $218 $34 

Reinsurance ceded

58 69 166 99 

Net other expenses

$106 $80 $384 $133 

78


Table of Contents

Metropolitan Life Insurance Company

(A Wholly-Owned Subsidiary of MetLife, Inc.)

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)

15. Related Party Transactions (continued)

Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated balance sheets was as follows at:

September 30, 2026December 31, 2025
Assumed CededAssumedCeded
(In millions)
Assets
Premiums, reinsurance and other
receivables (1)
$148 $10,936 $146 $11,017 

DAC and VOBA

108 (144)122 (149)

Total assets

$256 $10,792 $268 $10,868 
Liabilities

FPBs

$1,731 $— $1,941 $— 

PABs

7,940 — 8,441 — 
Other policy-related balances65 (61)69 (55)
Other liabilities884 8,959 934 9,582 

Total liabilities

$10,620 $8,898 $11,385 $9,527 

__________________

(1)Includes affiliated ceded PABs and FPBs.

The Company ceded two blocks of business to an affiliate on a 75% coinsurance with funds withheld basis. Certain contractual features of this reinsurance agreement qualify as embedded derivatives, which are separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivatives related to the funds withheld associated with this agreement are included within other liabilities and were ($52) million and ($37) million at September 30, 2026 and December 31, 2025, respectively. Net derivative gains (losses) associated with these embedded derivatives were $15 million for both the three months and nine months ended September 30, 2026, and ($6) million and ($10) million for the three months and nine months ended September 30, 2025, respectively.

Certain contractual features of the closed block agreement with MRC qualify as embedded derivatives, which are separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivative related to the funds withheld associated with this reinsurance agreement was included within other liabilities and was ($604) million and ($244) million at September 30, 2026 and December 31, 2025, respectively. Net derivative gains (losses) associated with the embedded derivative were $285 million and $360 million for the three months and nine months ended September 30, 2026, respectively, and ($77) million and ($179) million for the three months and nine months ended September 30, 2025, respectively.

16. Subsequent Events

Disposition

On October 29, 2026, Metropolitan Life Insurance Company distributed to MetLife, Inc., as a non-cash dividend, all of the issued and outstanding shares of its wholly-owned subsidiary, Missouri Reinsurance, Inc. (“MoRe”). On the dividend date, the Company’s stockholder’s equity was reduced by the aggregate carrying amount of MoRe’s assets in excess of their liabilities. The aggregate carrying value of MoRe’s assets in excess of their liabilities was $608 million at September 30, 2026.

Credit Facility

On November 9, 2026, MetLife, Inc. and MetLife Funding, Inc., a wholly-owned subsidiary of Metropolitan Life Insurance Company, amended and restated their $3.0 billion unsecured revolving credit facility (the “Credit Facility”) to, among other things, extend the maturity date to November 2031. As amended and restated, the Credit Facility will provide for borrowings and the issuance of letters of credit in an aggregate amount of up to $4.0 billion. All borrowings under the amended and restated Credit Facility must be repaid by November 7, 2031, except that letters of credit outstanding on that date may remain outstanding until no later than November 7, 2032.

79


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Index to Management’s Discussion and Analysis of Financial Condition and Results of Operations

Page

Forward-Looking Statements and Other Financial Information

81

Business

81

Results of Operations

83

Adopted Accounting Pronouncements

85

Future Adoption of Accounting Pronouncements

85

Risk Management

85

Subsequent Events

85

80


Table of Contents

Forward-Looking Statements and Other Financial Information

For purposes of this discussion, “MLIC,” the “Company,” “we,” “our” and “us” refer to Metropolitan Life Insurance Company, a New York corporation incorporated in 1868, and its subsidiaries. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”). Management’s narrative analysis of the Company’s results of operations is presented pursuant to General Instruction H(2)(a) of Form 10-Q. This narrative analysis should be read in conjunction with Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”), the cautionary language regarding forward-looking statements included below, the “Risk Factors” set forth in Part II, Item 1A, and the additional risk factors referred to therein, and the Company’s interim condensed consolidated financial statements included elsewhere herein.

This narrative analysis may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. See “Note Regarding Forward-Looking Statements” for cautionary language regarding forward-looking statements.

Business

Overview

MLIC is a provider of insurance, annuities and employee benefits. In the fourth quarter of 2025, the Company reorganized from three reportable segments (Group Benefits, Retirement and Income Solutions (“RIS”), and MetLife Holdings) to a single reportable segment to align with MetLife’s strategic initiatives, and the manner in which the chief operating decision maker (“CODM”) evaluates the performance of the business and allocates resources. Accordingly, certain products were reclassified within the product rollforwards. These changes were applied retrospectively for all periods presented and did not have an impact on prior period consolidated net income (loss). See “— Results of Operations — Overview” and Notes 1 and 2 of the Notes to the Interim Condensed Consolidated Financial Statements for further information.

Current Market Conditions

In the United States (“U.S.”), the Federal Open Market Committee (“FOMC”) took various actions in 2025 to promote employment and combat inflation, including lowering interest rates in the second half of the year and ending the process of quantitative tightening. While rates remained steady for most of 2026, the FOMC raised interest rates in September 2026. Labor market conditions, inflation, and financial and international developments, as well as other factors, could result in further policy adjustments. We are closely monitoring these and other political and economic conditions that might contribute to global market volatility and impact our business operations, investment portfolio and derivatives, such as global inflation, supply chain disruptions, acts of war, banking sector volatility and employment and work policies of the U.S. federal government.

Regulatory Developments

The following discussion on regulatory developments should be read in conjunction with “Business — Regulation” in the 2025 Annual Report, as amended or supplemented here.

Standards of Conduct, ERISA, Fiduciary Considerations, and Other Pension and Retirement Regulation

In 2021, the U.S. Department of Labor’s (“DOL”) final version of the prohibited transaction exemption (“PTE”) 2020-02 went into effect, which allows investment advice fiduciaries to receive compensation without violating the Employee Retirement Income Security Act of 1974 (“ERISA”), subject to impartial conduct standards and disclosure obligations aligned with U.S. Securities and Exchange Commission rules. In the preamble to PTE 2020-02, the DOL also provided its interpretation of the five-part test used to determine whether a person is acting as an ERISA investment advice fiduciary. In April 2024, the DOL finalized and published a regulation to change the definition of “fiduciary” for purposes of ERISA and parallel provisions of the Internal Revenue Code of 1986, as amended, when a financial professional, including an insurance producer, provides investment advice, and to amend various existing PTEs that financial professionals rely on when making recommendations.

81


Table of Contents

Shortly thereafter, litigation commenced challenging these changes and two federal district courts have since issued orders vacating the 2024 definition of an investment advice fiduciary and vacating the associated 2024 PTE amendments. Both of these orders were unopposed by the DOL. In light of the litigation, the DOL released a final rule vacating (i) the preamble to PTE 2020-02 (while leaving the original PTE intact) and (ii) its 2024 changes to the definition of an investment advice fiduciary, as well as its associated 2024 changes to various PTEs. As a result, the DOL has officially reinstated the original 1975 five-part regulatory test defining an investment advice fiduciary.

82


Table of Contents

Results of Operations

Overview

In the fourth quarter of 2025, the Company reorganized from three reportable segments (Group Benefits, RIS, and MetLife Holdings) to a single reportable segment to align with MetLife’s strategic initiatives, and the manner in which the CODM evaluates the performance of the business and allocates resources. Accordingly, certain products were reclassified within the product rollforwards. Additionally, the measure used to evaluate segment profitability changed from adjusted earnings to net income. These changes were applied retrospectively for all periods presented and did not have an impact on prior period consolidated net income (loss). Period‑to‑period changes in net income (loss) are evaluated by the Company as it relates to maintaining sufficient equity and capital to support insurance products and regulatory requirements. See Notes 1 and 2 of the Notes to the Interim Condensed Consolidated Financial Statements for further information.

Reinsurance Transactions

In 2025, the Company entered into a number of reinsurance agreements. See Note 8 of the Notes to the Consolidated Financial Statements included in the 2025 Annual Report for further information on these reinsurance transactions.

Net Income (Loss) Attributable to MLIC

Net income (loss) attributable to MLIC increased by $1.8 billion to $2.8 billion for the nine months ended September 30, 2026, compared to $1.1 billion for the nine months ended September 30, 2025.

Consolidated Results

Nine Months
Ended
September 30,
20262025
(In millions)
Revenues
Premiums$19,844 $19,564 
Universal life and investment-type product policy fees1,177 1,151 
Net investment income9,428 8,613 
Other revenues1,311 1,283 
Net investment gains (losses)(948)(823)
Net derivative gains (losses)699 (1,033)

Total revenues

31,511 28,755 
Expenses
Policyholder benefits and claims and policyholder dividends20,742 20,830 
Policyholder liability remeasurement (gains) losses100 8 

Market risk benefit remeasurement (gains) losses

(369)(127)
Interest credited to policyholder account balances2,876 2,826 

Amortization of deferred policy acquisition costs and value of business acquired

191 200 
Interest expense on debt75 85 

Other expenses, net of capitalization of deferred policy acquisition costs

4,411 3,728 
Total expenses28,026 27,550 
Income (loss) before provision for income tax3,485 1,205 
Provision for income tax expense (benefit)644 159 

Net income (loss)

2,841 1,046 
Less: Net income (loss) attributable to noncontrolling interests(7)(9)
Net income (loss) attributable to Metropolitan Life Insurance Company$2,848 $1,055 

83


Table of Contents

Nine Months Ended September 30, 2026 Compared with the Nine Months Ended September 30, 2025

Revenues

Total revenues increased $2.8 billion, or 10%, to $31.5 billion for the nine months ended September 30, 2026 from $28.8 billion in the prior period, primarily due to the following:

•Net derivative gains in the current period compared to losses in the prior period were primarily due to favorable changes in the estimated fair value of the underlying assets from embedded derivatives related to funds withheld on reinsurance agreements. See “— Derivatives — Net Derivative Gains (Losses)” in the 2025 Annual Report for information regarding the use of derivatives to hedge market risk.

•An increase in net investment income was driven by higher income on fixed maturity securities. See “— Investments — Overview” in the 2025 Annual Report for information regarding management of our investment portfolio.

Partially offset by:

•Higher net investment losses were driven by higher impairments on real estate investments and higher losses on other limited partnership interests, partially offset by gains on foreign currency transactions in the current period compared to losses in the prior period.

Expenses

Total expenses increased $476 million, or 2%, to $28.0 billion for the nine months ended September 30, 2026 from $27.6 billion in the prior period, primarily due to the following:

•Higher other expenses, net of capitalization of deferred policy acquisition costs, were primarily due to higher reinsurance and employee-related expenses.

•Policyholder liability remeasurement losses increased primarily due to the actuarial assumption review. See “— Additional Information - Actuarial Assumption Review” for the results of the actuarial assumption review.

Partially offset by:

•An increase in market risk benefit remeasurement gains was primarily driven by increases in U.S. long-term interest rates in the current period compared to decreases in the prior period, partially offset by (i) certain key equity indexes increasing less significantly in the current period compared to the prior period and (ii) ceded reinsurance. See Note 5 of the Notes to the Interim Condensed Consolidated Financial Statements for information on the Company’s market risk benefits.

Income Taxes

The current period effective tax rate on income before provision for income tax was 18% compared to the U.S. statutory rate of 21% primarily due to tax benefits from:

•Non-taxable investment income

•Low income housing and other tax credits, partially offset by the impact of tax equity investments

The prior period effective tax rate on income before provision for income tax was 13% compared to the U.S. statutory rate of 21% primarily due to tax benefits from:

•Non-taxable investment income

•Low income housing and other tax credits, partially offset by the impact of tax equity investments

•Corporate tax deduction for stock-based compensation

Additional Information - Actuarial Assumption Review

The actuarial assumption review resulted in a loss of $51 million and a gain of $20 million for the nine months ended September 30, 2026 and 2025, respectively:

84


Table of Contents

Nine Months Ended September 30,Variance
Assumptions20262025
(In millions, net of income tax)
Economic$(1)$(34)$33 
Mortality(44)13 (57)
Morbidity49 (90)139 
Policyholder behavior(107)15 (122)
Operational52 116 (64)
Total$(51)$20 $(71)

•The $71 million decrease was primarily driven by (i) updates to policyholder behavior assumptions in the long-term care business related to refinements to the lapse assumption, (ii) updates to operational assumptions related to future premium rate increases for the long-term care business, and (iii) less favorable mortality experience in the structured settlements, pension risk transfer, variable annuity and term life businesses, partially offset by favorable morbidity in the long-term care business.

Adopted Accounting Pronouncements

See Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements.

Future Adoption of Accounting Pronouncements

See Note 1 of the Notes to the Interim Condensed Consolidated Financial Statements.

Risk Management

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Risk Management” in the 2025 Annual Report for information on our risk management.

Subsequent Events

See Note 16 of the Notes to the Interim Condensed Consolidated Financial Statements for information regarding (i) the non-cash dividend distribution of Missouri Reinsurance, Inc. to MetLife, Inc. and (ii) the amended and restated unsecured revolving credit facility.

85


Table of Contents

Item 4. Controls and Procedures

Management, with the participation of the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), as of the end of the period covered by this report. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective.

There were no material changes to the Company’s internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II — Other Information

Item 1. Legal Proceedings

See Note 14 of the Notes to the Interim Condensed Consolidated Financial Statements.

Item 1A. Risk Factors

Certain factors that may affect the Company’s business or operations are described under “Risk Factors” in Part I, Item 1A, of the 2025 Annual Report. There have been no material changes to our risk factors from the risk factors previously disclosed in the 2025 Annual Report.

Item 5. Other Information

Securities trading plans

During the three months ended September 30, 2026, none of our Section 16 officers or directors (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).

86


Table of Contents

Item 6. Exhibits

Incorporated by Reference
Exhibit No.DescriptionForm File NumberExhibit Filing DateFiled or Furnished Herewith
31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X
31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X
32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X
32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X
101.SCHInline XBRL Taxonomy Extension Schema Document.X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.X
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document. X
104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).X

87


Table of Contents

Glossary

Throughout this Form 10-Q, the Company may use certain abbreviations, acronyms and terms which are further detailed below.

A.M. BestA.M. Best Company, Inc.Farmer MacFederal Agricultural Mortgage Corporation
ABOAccumulated Benefit ObligationsFASBFinancial Accounting Standards Board
ABS & CLOAsset-Backed Securities and Collateralized Loan ObligationsFHLBNYFederal Home Loan Bank of New York
ACLAllowance For Credit LossFINRAFinancial Industry Regulatory Authority
AFSAvailable-For-SaleFIOFederal Insurance Office
AIArtificial IntelligenceFitchFitch Ratings Inc.
ALMAsset/Liability Management

FPBs

Future Policy Benefits

Alt-AAlternative Residential Mortgage LoansFSOCFinancial Stability Oversight Council
AOCI

Accumulated Other Comprehensive Income (Loss)

FVOFair Value Option
ASOAdministrative Services-OnlyGAAPAccounting principles generally accepted in the United States of America
ASUAccounting Standards UpdateGCCGroup Capital Calculation
Authorized Control Level RBCAuthorized Control Level RBC, calculated in the manner prescribed by the NAICGICsGuaranteed Interest Contracts
CCPACalifornia Consumer Privacy ActGMABsGuaranteed Minimum Accumulation Benefits
CEOChief Executive Officer

GMCR

Guaranteed Minimum Crediting Rates
CFEs

Collateralized Financing Entities

GMDBsGuaranteed Minimum Death Benefits
CFOChief Financial OfficerGMIBsGuaranteed Minimum Income Benefits
CFPBConsumer Financial Protection BureauGMWBsGuaranteed Minimum Withdrawal Benefits
CFTCCommodity Futures Trading CommissionGMXBsGuaranteed Minimum Benefits
CISOChief Information Security OfficerIBNPIncurred But Not Paid
CLOsCollateralized Loan ObligationsIBNRIncurred But Not Reported
CMBSCommercial Mortgage-Backed SecuritiesIMRInterest Maintenance Reserve
CODMChief Operating Decision MakerIRSInternal Revenue Service
COLI

Company-Owned Life Insurance Policies

LDTILong-Duration Targeted Improvements
Company Action Level RBCMinimum level of TAC before corrective action commences is twice authorized control level RBCLDTI Transition Date

January 1, 2021

Credit FacilityUnsecured revolving credit facilityLTVLoan-To-Value
CROChief Risk OfficerMetLife FundingMetLife Funding, Inc.
Cybersecurity Model LawNAIC’s Insurance Data Security Model LawMLICMetropolitan Life Insurance Company
DACDeferred Policy Acquisition CostsMoody’sMoody’s Investors Service, Inc.
Dodd-FrankDodd-Frank Wall Street Reform and Consumer Protection ActMoReMissouri Reinsurance, Inc.
DOL

U.S. Department of Labor

MRB

Market Risk Benefit

DPLDeferred Profit LiabilityMRC

MetLife Reinsurance Company of Charleston

DSCRDebt Service Coverage RatiosMTLMetropolitan Tower Life Insurance Company
ERCEnterprise Risk CommitteeNAIC

National Association of Insurance Commissioners

ERISAEmployee Retirement Income Security Act of 1974NAVNet Asset Value
ERMEnterprise Risk ManagementNGEsNon-Guaranteed Elements
Exchange ActSecurities Exchange Act of 1934, as amendedNIFONet investment in a foreign operation

88


Table of Contents

NPRNet Premium RatioNon-Bank SIFINon-Bank Systemically Important Financial Institution
NQM

Nonqualified Residential Mortgage

S&PStandard & Poor’s Global Ratings
NRSRONationally Recognized Statistical Rating OrganizationsSCLSpecial Considerations Letter
NYDFSNew York State Department of Financial ServicesSEC

U.S. Securities and Exchange Commission

OCIOther Comprehensive Income (Loss)SSGStructured Securities Group
OLPIOther Limited Partnership InterestsStatutory CodificationCodification of Statutory Accounting Principles
OTCOver-the-CounterStructured ProductsRMBS, ABS & CLO and CMBS
OTC-bilateralBilateral contracts between two counterpartiesSuperintendentNew York Superintendent of Financial Services
OTC-clearedOTC derivatives are cleared and settled through central clearing counterpartiesTACTotal Adjusted Capital, calculated in the manner prescribed by the NAIC
PABsPolicyholder Account BalancesTRRsTotal Rate of Return Swaps
PBOProjected Benefit ObligationU.S.

United States

PCAOBPublic Company Accounting Oversight BoardULSG

Universal and Variable Universal Life Policies with Secondary Guarantees

PTEProhibited Transaction ExemptionUREVUnearned Revenue
RBCRisk-Based CapitalVIEsVariable Interest Entities

REJVs

Real Estate Joint Ventures

VM

Valuation Manual

RISRetirement and Income SolutionsVOBAValue of Business Acquired
RMBSResidential Mortgage-Backed SecuritiesVOCRAValue of Customer Relationships Acquired
ROU

Right-of-Use

VODAValue of Distribution Agreements

89


Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

METROPOLITAN LIFE INSURANCE COMPANY
By:/s/ Adrienne O’Neill

Name:  Adrienne O’Neill

Title:    Executive Vice President

             and Chief Accounting Officer

             (Authorized Signatory and Principal

             Accounting Officer)

Date: November 10, 2026

90

View source ↗ · 中文页面